Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
- Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and Jaguar family company Napo Pharmaceuticals ("Napo") today announced that, on January 29, 2025, they extended their collaboration with Streeterville related to Napo's plans to develop its NP-300 drug product candidate for the symptomatic relief of diarrhea and dehydration in cholera patients and pursue a possible Tropical Disease Priority Review Voucher ("TDPRV") from the U.S. Food and Drug Administration ("FDA") for this indication. With the sunset of the FDA's Rare Pediatric Disease PRV program in December 2024, and the sunset of the FDA's Medical Countermeasures PRV Program in October 2023, the TDPRV Program is currently the FDA's only active PRV program - so there will possibly be fewer PRVs available for purchase, which could increase the value of TDPRVs, spurring increased interest and investment in tropical diseases.
- 02/18/2025
|
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
- SAN FRANCISCO, CA / ACCESS Newswire / February 13, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Tuesday, February 18, 2025 at the Emerging Growth Conference. Participation Instructions for Jaguar Health's Virtual Presentation at the Emerging Growth Conference When: Tuesday, February 18, 2025 from 3:55 - 4:05 PM Eastern Standard Time Where: Online (Click Here) Registration link for conference: Click Here Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.
- 02/13/2025
|
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
- Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in late 2025/early 2026 SAN FRANCISCO, CA / ACCESS Newswire / February 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena Biosciences, Inc. (Magdalena), the joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF) (CBOE CA:FH) (FSE:7QS) to develop novel, natural prescription medicines derived from plants for mental health indications, is presenting in person on Monday, February 10, 2025 at 2:30 PM Eastern at the BIO CEO & Investor Conference in New York City. "I very much look forward to providing an overview of Magdalena at this conference and meeting with potential partners and investors at this event," Dr. Brunke said.
- 02/06/2025
|
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
- Trial taking place at Sheikh Khalifa Medical City , a flagship United Arab Emirates hospital and largest teaching medical center in Abu Dhabi Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID Proof-of-concept (POC) data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for these rare/orphan diseases SAN FRANCISCO, CA / ACCESS Newswire / February 3, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that the first short bowel syndrome with intestinal failure (SBS-IF) patient has been dosed in the independent investigator-initiated pediatric POC trial (IIT) of crofelemer, Jaguar's novel plant-based antidiarrheal prescription drug. The first infant with microvillus inclusion disease (MVID) was dosed as part of the same IIT two weeks ago.
- 02/03/2025
|
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
- Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported in up to 85% Crofelemer, approved by the FDA under the brand name Mytesi® for HIV-related diarrhea, has demonstrated a significant benefit in improving gastrointestinal symptoms, including diarrhea, abdominal pain and discomfort, incontinence, bloating and constipation, when studied in populations with HIV-related diarrhea, cancer therapy-related diarrhea, and IBS Crofelemer could have a significant supportive impact on GLP-1 therapies, one of the fastest growing classes of drugs, estimated to be a $56 billion global market in 2025 and projected to grow at a CAGR of 21% to $322 billion 20341 SAN FRANCISCO, CA / ACCESS Newswire / January 29, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced Napo's filing of a broad defining provisional patent application with the U.S. Patent and Trademark Office (USPTO) for crofelemer, Jaguar's novel plant-based FDA-approved gastrointestinal normalizing prescription drug, to mitigate the gastrointestinal side effects associated with glucagon-like peptide-1 (GLP-1) receptor agonists and antagonists, together with other incretin-based therapies including glucose-dependent insulinotropic polypeptide (GIP) agonists and antagonists, and glucagon-agonist drugs. GLP-1 and GIP drugs are analogs for incretin hormones that are released by the gut and bind to receptors in the brain and gastrointestinal tract, suppressing appetite, which consequently leads to body weight loss.
- 01/29/2025
|
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025
- Trial taking place at Sheikh Khalifa Medical City , a flagship tertiary hospital in the United Arab Emirates POC data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for MVID Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome with intestinal failure (SBS-IF) SAN FRANCISCO, CA / ACCESS Newswire / January 22, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that the first patient has been dosed in the independent investigator-initiated POC trial of crofelemer, Jaguar's novel plant-based anti-diarrheal prescription drug, for the rare disease indication of MVID in pediatric patients. POC data generated from this study potentially in the first half of 2025 could lead to reimbursed early patient access to crofelemer for this indication in certain European countries.
- 01/22/2025
|
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 8, 2025, the Company granted 15,000 restricted stock units (RSUs) to New Employee 1, 15,000 RSUs to New Employee 2, and 45,000 RSUs to New Employee 3. The RSUs for New Employee 1 and New Employee 2 vest over one year starting from each employee's date of hire, and the RSUs for New Employee 3 vest equally over three years, with one-third of the shares vesting each year starting from New Employee 3's date of hire.
- 01/10/2025
|
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase
- SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat on January 13, 2025 at the Lytham Partners 2025 Investor Healthcare Summit and in person on January 14, 2025 at Biotech Showcase. Participation Instructions for Jaguar Health's Virtual Fireside Chat at the Lytham Partners 2025 Investor Healthcare Summit When: Monday, January 13, 2025 at 12:00 PM Eastern Standard TimeWhere: Online (Click Here).
- 01/08/2025
|
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
- Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in 2025 SAN FRANCISCO, CA / ACCESSWIRE / January 7, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena Biosciences, Inc. (Magdalena), the joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(CBOE CA:FH) (FSE:7QS) to develop novel, natural prescription medicines derived from plants for mental health indications, is presenting in person on Sunday, January 12, 2025 at the Annual Neuroscience Innovation Forum in San Francisco, CA. "I very much look forward to providing an overview of Magdalena at this conference and meeting with potential partners and investors at this event," Dr. Brunke said.
- 01/07/2025
|
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
- Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications The import was conducted in collaboration with the government of Peru Steven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit in Peru Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESSWIRE / December 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Magdalena Biosciences, Inc. ("Magdalena"), a joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(Cboe CA:FH)(FSE:7QS) ("Filament" or "Filament Health"), successfully completed an import of six kilograms of coca leaf from Peru to Filament's Metro Vancouver research and development facility.
- 12/19/2024
|
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
- The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of first IIT proof-of-concept results potentially in Q1 2025 Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both MVID and SBS-IF SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that Napo's Phase 2 study to evaluate the efficacy of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for the indication of MVID in pediatric patients, has been initiated. "The initiation of this double blind, placebo-controlled study in pediatric MVID patients is a key milestone for Jaguar," said Lisa Conte, Jaguar's founder, president, and CEO.
- 12/18/2024
|
FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera
- World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Crofelemer previously granted orphan-drug designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome and microvillus inclusion disease SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2024 / Jaguar Health (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to crofelemer, the company's novel plant-based prescription drug, for treatment of diarrhea in cholera. "We are very pleased that crofelemer has been granted orphan-drug designation for this important indication," said Steven King, PhD, Jaguar's Chief Sustainable Supply, Ethnobotanical Research & IP Officer.
- 12/17/2024
|
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
- Crofelemer is the subject of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - for the rare disease indications of microvillus inclusion disease (MVID) and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of IIT proof-of-concept results potentially in Q2 2025 Virtual event 11:00 AM to 12:00 PM Eastern Registration open now for financial and business community; Click here to register Massimo Radaelli, PhD, CEO of the rare disease-focused Jaguar family company Napo Therapeutics and President of Jaguar International, named ‘ Best CEO BioPharmaceuticals of the Year ' SAN FRANCISCO, CA / ACCESSWIRE / December 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Ladenburg Thalmann is hosting a Scientific Showcase webinar on Wednesday, December 18, 2024 from 11:00 a.m. to 12:00 p.m.
- 12/13/2024
|
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
- Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 OnTarget trial evaluating crofelemer for prophylaxis of CTD The majority of patients in the OnTarget placebo group on abemaciclib and pertuzumab-based therapies required dose reduction or elimination SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today provided an overview of the data from the poster presentation conducted yesterday, December 11, 2024, at the San Antonio Breast Cancer Symposium (SABCS) about the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 OnTarget trial, which indicates that crofelemer achieved statistically significant results in this subgroup. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy.
- 12/12/2024
|
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)
- Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of CTD SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the data from the recently conducted analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 OnTarget trial, which indicate that crofelemer achieved significant results in this subgroup, will be the subject of a poster presentation on December 11, 2024 during the 12:30 - 2:00 p.m. CST Poster Session 1 at the San Antonio Breast Cancer Symposium (SABCS), which takes place December 10-13, 2024 in San Antonio, Texas.
- 12/09/2024
|
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
- The study is one of five clinical efforts - three IIT proof-of-concept studies and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and/or microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder, in the US, EU, and/or Middle East/North Africa (MENA) regions; availability of IIT proof-of-concept results potentially in Q2 2025 Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that an independent IIT in the U.S. to evaluate the efficacy and safety of crofelemer, Jaguar's novel plant-based anti-diarrheal prescription drug, for the rare disease indication of short bowel syndrome with intestinal failure (SBS-IF) in adults has begun. An overview of the study can be viewed on the ClinicalTrials.gov website.
- 12/06/2024
|
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine
- Canalevia®-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree Crofelemer, the active ingredient in Canalevia CA-1, is the subject of Jaguar's recently conducted Phase 3 OnTarget trial in humans for cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / December 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that an article about Canalevia-CA1 (crofelemer delayed-release tablets), Jaguar's prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, has been published in PetVet Magazine and can be viewed by clicking here. Canalevia-CA1 is conditionally approved by the U.S. Food and Drug Administration for the treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any approval from the FDA.
- 12/05/2024
|
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference
- SAN FRANCISCO, CA / ACCESSWIRE / November 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on December 3, 2024 at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference, and present virtually on December 5, 2024 at the Emerging Growth Conference. Participation Instructions for Jaguar Health's In-Person Presentation at NobleCon20 When: Tuesday, December 3, 2024 at 10:30 - 10:55 AM Eastern Standard TimeWhere: Presentation Room 3, Florida Atlantic University, Executive Education Complex, Boca Raton, FloridaRegistration link for conference: Click Here Replay: A video webcast of the presentation will be available the following day as part of a complete catalog of presentations available at www.nobleconference.com and on Noble's Channelchek investor portal: www.channelchek.com.
- 11/25/2024
|
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
- Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs Canalevia®-CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA Jaguar is attending the December 3-5 Pet Connect conference and is available for NP300 partnership discussions at the event SAN FRANCISCO, CA / ACCESSWIRE / November 22, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it is seeking a partner to fund and execute the development and commercialization of NP300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhea in dogs, in exchange for commercial rights to the product in the U.S. NP300 is a novel antisecretory drug with a similar mechanism of action to Canalevia®-CA1 (crofelemer delayed-release tablets), the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. NP300 has demonstrated safety in dogs and is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer.
- 11/22/2024
|
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
- Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Therapeutics has been named "Best Pharmaceuticals Innovator of the Year - Europe" by The European, a quarterly business publication published by CP Media Global Ltd in London. "We are very honored to receive this award," said Massimo Radaelli, PhD, Chief Executive Officer of Napo Therapeutics and President of Jaguar International, "as we continue to be laser-focused on our mission of expanding access to crofelemer in Europe for orphan and rare diseases.
- 11/19/2024
|
Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript
- Jaguar Health, Inc. (NASDAQ:JAGX ) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President & Chief Executive Officer Pravin Chaturvedi - Chief Scientific Officer Carol Lizak - Chief Financial Officer Operator [Call Starts Abruptly] before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage, which may not make -- achieve scientific objectives or meet changing regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those complicated in such forward-looking statements.
- 11/15/2024
|
Jaguar Health Reports Third Quarter 2024 Financial Results
- The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million Jaguar reported significant results in breast cancer patients in its phase 3 OnTarget trial for its cancer supportive care drug crofelemer; results in breast cancer patients accepted for poster presentation on December 11, 2024 at the San Antonio Breast Cancer Symposium (SABCS) Jaguar initiated commercial launch in October 2024 for Gelclair ®, the company's third prescription product, in alignment with Jaguar's focus on cancer supportive care Jaguar is initiating two Phase 2 trials in Q4, 2024 and supporting multiple investigator-initiated proof-of-concept studies ("IIT") of crofelemer for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU, and Middle East/North Africa (MENA) regions; results of IITs expected by the end of 2024 and throughout 2025 REMINDER: Jaguar to host investor webcast Wednesday, November 13th at 8:30 a.m. Eastern regarding Q3 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / November 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated third-quarter 2024 financial results and provided Company updates.
- 11/13/2024
|
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
- Click here to register for investor webcast Company plans to file its Earnings Report on November 13, 2024 on Form 10-Q for the quarter ended September 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, November 13, 2024 at 8:30 a.m. Eastern to review third-quarter 2024 financials and provide corporate updates.
- 11/11/2024
|
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
- Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / November 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the U.S. Food and Drug Administration (FDA) has approved renewal of Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy.
- 11/06/2024
|
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
- Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) A second late-breaking abstract related to the OnTarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation at SABCS SAN FRANCISCO, CA / ACCESSWIRE / November 4, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaking abstract about the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 OnTarget trial, which indicates that crofelemer achieved significant results in this subgroup, has been accepted for a poster presentation on December 11, 2024 at the San Antonio Breast Cancer Symposium (SABCS). Patients with breast cancer accounted for the majority of participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.
- 11/04/2024
|
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
- It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the abstracts are now available for two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, that show a benefit in patients with chronic refractory diarrhea and are the subject of poster presentations taking place today, October 29, 2024, at the American College of Gastroenterology Annual Scientific Meeting (ACG 2024) in Philadelphia, Pennsylvania. Descriptions of both studies appear below, along with a link to the virtual ACG 2024 ePoster Hall page for each study - which display the poster for each study and provide a short audio presentation of the posters.
- 10/29/2024
|
Small-cap biotech Jaguar Health's stock jumps 7% as it launches treatment for oral mucositis in cancer patients
- The stock of small-cap biotech Jaguar Health Inc. rose 7% on Wednesday, after the company launched its gelclair treatment for oral mucositis, a common side effect suffered by head and neck cancer patients.
- 10/16/2024
|
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
- Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Severe mucositis/pharyngitis occurred in 70% of head and neck cancer patients in third-party study SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") has initiated the commercial launch of the FDA-approved oral mucositis prescription product Gelclair in the U.S. "Cancer is chaotic, because patients feel a loss of control - over their life, their treatment, and their supportive care needs," said Catherine Collis, Jaguar's Senior Vice President of Growth Strategy. "Jaguar's mission is to change patients' lives for the better, especially in the area of supportive care for complex disease states like cancer.
- 10/16/2024
|
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, CA / ACCESSWIRE / October 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 7, 2024, the Company granted 80,000 restricted stock units (RSUs) to New Employee 1 and 15,000 RSUs to each of four other new employees ("New Employees 2-5"). The RSUs for New Employee 1 vest equally over three years, with one-third of the shares vesting each year starting from New Employee 1's date of hire.
- 10/11/2024
|
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
- Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in 2025 SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena Biosciences, Inc. (Magdalena), the joint venture recently formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(CBOE CA:FH)(FSE:7QS) to develop novel, natural prescription medicines derived from plants for mental health indications, is presenting on Wednesday, October 16, 2024 at 10:15 a.m. PDT at the BIO Investor Forum, which takes place October 15-16 in San Francisco, California.
- 10/10/2024
|
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
- SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a late-breaking abstract evaluating the incidence, severity and management of diarrhea from targeted therapies with or without standard chemotherapy in the cohort of adult patients with breast cancer in the placebo group of the OnTarget phase 3 study recently conducted by Jaguar family company Napo Pharmaceuticals, was submitted by the study's primary investigators to a relevant oncology conference for consideration for a presentation. In this study 142 patients with solid tumors received placebo tablets and nearly 75 of them were patients with breast cancer receiving targeted therapies with or without standard chemotherapy.
- 10/08/2024
|
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
- Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea OnTarget results in breast cancer patients have been submitted to a relevant oncology conference SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the company's Phase 3 OnTarget trial indicate that crofelemer achieved statistical significance in this subgroup. Patients with breast cancer accounted for nearly 180 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Jaguar family company Napo Pharmaceuticals for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.
- 10/01/2024
|
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors
- Jaguar's commercial focus on cancer supportive care aims to use the best tools and techniques that assess the quality of life of cancer patients and survivors and deliver solutions to address these unmet needs - Commonly used tools and techniques fail to measure what patients are most concerned about Jaguar family company Napo Pharmaceuticals sponsored the "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer" SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Stacey Tinianov, MPH, the founder of Advocates for Collaborative Education (ACE) and a member of Jaguar's Scientific Advisory Board, will conduct a poster presentation on September 27, 2024 at the American Society of Clinical Oncology (ASCO) Quality Care Symposium. The presentation, titled "Measuring what really matters: Advocacy-led co-creation and accrual of a pan-cancer QoL survey," will describe the methodologies and best practices used to design and execute "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer.
- 09/26/2024
|
Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
- SAN FRANCISCO, CA / ACCESSWIRE / September 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference , taking place virtually on Tuesday, October 1, 2024. Company Webcast The webcasted presentation will take place at 1:15pm Eastern on Tuesday, October 1, 2024.
- 09/25/2024
|
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
- Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Up to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals (Napo) is exhibiting Gelclair ® , the FDA-approved oral mucositis prescription product, at the American Society for Radiation Oncology (ASTRO) Annual Meeting , which takes place September 29 - October 2, 2024 in Washington, DC. Jaguar plans to begin the U.S. commercial launch in October 2024 for Gelclair.
- 09/24/2024
|
Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference
- SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on September 19, 2024 at the MedInvest Biotech & Pharma Investor Conference and participate in one-on-one meetings at the event, which is taking place September 18-19 in New York City. Participation Instructions for Jaguar Health's Presentation at the MedInvest Biotech & Pharma Investor Conference When: Thursday, September 19, 2024 from 9:55 AM Eastern to 10:10 AM Eastern Registration link for presentation: Click Here About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain.
- 09/16/2024
|
Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care
- FDA-approved Gelclair ® is company's third commercialized prescription product Susan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family company Napo Pharmaceuticals. "Sue is a dynamic and proven commercial leader with 30 years of experience in the biopharmaceuticals industry - including 15 years of recent experience in the oncology market - building high-performing teams and exceeding sales targets.
- 09/10/2024
|
Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference
- SAN FRANCISCO, CA / ACCESSWIRE / September 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will be presenting virtually, and meeting virtually with investors, at the H.C. Wainwright 26th Annual Global Investment Conference, which takes place September 9-11, 2024.
- 09/06/2024
|
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
- Company's Canalevia®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / September 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Service Dog Month, a time devoted to raising awareness and showing appreciation for the extraordinary work service dogs do every day for the people in their care. "September is National Service Dog Month.
- 09/05/2024
|
New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company's Near-Term Commercial & Development Milestones
- Click here to view interview video Paramount near-term activities include planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair ® and results from independent, investigator-initiated trials of crofelemer for rare diseases SAN FRANCISCO, CA / ACCESSWIRE / September 4, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a new Innovators with Jane King video interview of Lisa Conte, Jaguar's founder, president, and CEO, is available and can be viewed by clicking here . "Our paramount near-term activities are our planned October 2024 commercial launch of the FDA-approved oral mucositis prescription product Gelclair in the U.S. and progressing our rare disease development business," said Conte.
- 09/04/2024
|
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
- New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the country of Jordan's Industrial Property Protection Directorate has issued a new patent to Jaguar family company Napo Pharmaceuticals (Napo) for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO.
- 08/27/2024
|
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
- Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Eduardo Zimmer, Ph.D., a key collaborator with Magdalena Biosciences ("Magdalena"), the joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(CBOE CA:FH)(FSE:7QS) to develop novel, natural prescription psychoactive medicines derived from plants for mental health indications, is the 2024 recipient of the prestigious Blas Frangione Early Career Achievement Award.
- 08/20/2024
|
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
- New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Hong Kong's Intellectual Property Department has issued a new patent to Jaguar family company Napo Pharmaceuticals for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO.
- 08/19/2024
|
Jaguar Health, Inc. (JAGX) Q2 2024 Earnings Call Transcript
- Jaguar Health, Inc. (NASDAQ:JAGX ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President & Chief Executive Officer Pravin Chaturvedi - Chief Scientific Officer Cathy Collis - Senior Vice President of Growth Strategy Carol Lizak - Chief Financial Officer Conference Call Participants Operator [Call starts abruptly] Before I turn the call over to the management, I would like to remind you that the management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and productive initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
- 08/13/2024
|
Jaguar Health Reports Second Quarter 2024 Financial Results
- The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in support of FDA discussion; Jaguar to explore possible approval pathway for crofelemer in breast and lung cancer based on phase 3 results Jaguar planning to begin commercial launch in October 2024 for Gelclair ®, the company's third prescription product Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure REMINDER: Jaguar to host investor webcast Tuesday, August 13th at 8:30 a.m. Eastern regarding Q2 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated second-quarter 2024 financial results and provided Company updates.
- 08/13/2024
|
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial's Clinically Meaningful Results in Breast and Lung Cancer Patients
- Jaguar to explore approval pathway for crofelemer in breast and lung cancer based on phase 3 results Click here to register for investor webcast Company plans to file its Earnings Report on August 13, 2024 on Form 10-Q for the quarter ended June 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / August 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Tuesday, August 13, 2024 at 8:30 a.m. Eastern to review second-quarter 2024 financials and provide corporate updates.
- 08/12/2024
|
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
- Dr. Elisabetsky is also an advisor to Magdalena Biosciences , the joint venture formed by Jaguar and Filament Health focused on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions As announced , Jaguar recently executed an out-license deal with Magdalena Biosciences for a botanical drug candidate for possible schizophrenia and psychoses indications and for development with potential corporate partners; the global schizophrenia treatment market valued at $8.29 billion SAN FRANCISCO, CA / ACCESSWIRE / August 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Elaine Elisabetsky, PhD, is conducting a talk on Friday, August 2, 2024 from 12:30 PM - 2:00 PM Central covering several decades of research on plant-based medicines used to manage schizophrenia. Dr. Elisabetsky's talk is part of the annual Norman R.
- 08/02/2024
|
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
- It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, showed a benefit in patients with chronic refractory diarrhea and have been accepted for poster presentations at the American College of Gastroenterology Annual Scientific Meeting, which takes place October 25-30, 2024 at the Pennsylvania Convention Center in Philadelphia. "We are very excited that crofelemer continues to demonstrate clinical robustness in responder analysis trials for multiple gastroenterological conditions - including functional diarrhea and chronic idiopathic diarrhea.
- 08/01/2024
|
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
- New patent issued for core rare disease target indication for crofelemer Jaguar has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome (SBS) and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with proof-of-concept results expected before the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / July 31, 2024 / Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that the European Patent Office has issued a new patent to Napo for methods of preventing, ameliorating and/or treating diarrhea associated with congenital diarrheal disorders (CDDs) using a proanthocyanidin polymer composition such as crofelemer, Napo's novel plant-based prescription drug. "We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of MVID, an ultrarare CDD," said Lisa Conte, Jaguar's founder, president, and CEO.
- 07/31/2024
|
Why Is Jaguar Health (JAGX) Stock Down 55% Today?
- Jaguar Health (NASDAQ: JAGX ) stock is taking a beating on Tuesday after the commercial-stage pharmaceuticals company reported results from a Phase 3 clinical trial. This trial covers the use of crofelemer as a treatment for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy.
- 07/23/2024
|
Jaguar Health's stock slides 68% after cancer trial fails to meet main goal
- Jaguar Health Inc.'s stock JAGX, +0.23% tumbled 68% early Tuesday, after the biotech said a late-stage trial of a cancer drug failed to meet its main goal across all tumor types. San Francisco-based Jaguar said the Phase 3 trial of its crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy did not meet its primary endpoint.
- 07/23/2024
|
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
- Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer, including lung cancer.
- 07/23/2024
|
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
- Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here to register for webcast Jaguar expands Make Cancer Less Shitty (MCLS) patient advocacy program to incorporate select group of MCLS Ambassadors - cancer survivors who understand the realities of cancer and are no longer willing to accept debilitating side effects of cancer treatments as an acceptable trade-off for survival Cancer patients with diarrhea are 40% more likely to discontinue their therapy; oral mucositis affects up to 40% of patients undergoing chemotherapy and approximately 90% of those receiving chemoradiation for head and neck cancers, with more than one-third of patients discontinuing cancer treatment because of the condition SAN FRANCISCO, CA / ACCESSWIRE / July 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it will hold an investor webcast on Tuesday, July 23, 2024 at 8:30 AM Eastern to review results for the company's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. A press release announcing the results will be issued that morning, prior to the webcast.
- 07/18/2024
|
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
- JAGX's securities continue to be listed and traded on Nasdaq Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that Jaguar has regained compliance with Nasdaq's minimum bid price requirement. "We are very happy that Jaguar has regained compliance with Nasdaq.
- 06/26/2024
|
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
- Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea and oral mucositis In honor of World Rainforest Day (June 22), Jaguar is proud to share RealPharma podcast interview with ethnobotanist Dr. Steven King SAN FRANCISCO, CA / ACCESSWIRE / June 21, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Annual Meeting of Stockholders held June 21, 2024 (the "Annual Meeting"). Five proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting.
- 06/21/2024
|
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
- Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis Cancer patients with diarrhea are 40% more likely to discontinue their therapy, and up to 40% of cancer patients experience the painful side effect of oral mucositis SAN FRANCISCO, CA / ACCESSWIRE / June 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it will hold an investor webcast on or before July 23, 2024 to provide results for the company's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. The webcast, which will provide updates on Jaguar's advancing cancer supportive care portfolio, will include members of Jaguar's scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis.
- 06/12/2024
|
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, CA / ACCESSWIRE / June 7, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 4, 2024, the Company granted 1,111 restricted stock units (RSUs) to one new employee. These RSUs vest over one year starting from this new employee's date of hire.
- 06/07/2024
|
US Stocks Mixed; Li Auto Shares Plummet After Q1 Results
- U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 0.5% on Monday. Following the market opening Monday, the Dow traded down 0.19% to 39,925.91 while the NASDAQ rose 0.50% to 16,769.45. The S&P 500 also rose, gaining, 0.19% to 5,313.25. Check This Out: Top 3 Financial Stocks That Are Set To Fly This Quarter Information technology shares rose by 0.9% on Monday. In trading on Monday, real estate shares fell by 0.6%. Shares of The company posted revenue growth of 36.4% year-on-year to $3.55 billion, missing the analyst consensus estimate of $3.84 billion. Adjusted net earnings per ADS was 17 cents missed the analyst consensus estimate of 35 cents. GT Biopharma, Inc. GTBP+161.4%+ Free Alerts shares shot up 142% to $7.54. GT Biopharma, last week, posted a narrower-than-expected quarterly loss. Shares of Tantech Holdings Ltd TANH+79.5%+ Free Alerts got a boost, surging 119% to $1.44. MultiMetaVerse Holdings Limited MMV+187.8%+ Free Alerts shares were also up, gaining 102% to $1.25. MultiMetaVerse Holdings signed a non-binding term sheet to acquire 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries. Virios Therapeutics, Inc. VIRI-47.9%+ Free Alerts shares dropped 49% to $0.1790 after the company priced a $1.7 million pubic offering of 8.5 million shares of common stock at $0.20 per share. Shares of Akoustis Technologies, Inc. AKTS-44.7%Get Free Report were down 47% to $0.1899 after Qorvo won a jury verdict against the company in a trade secret misappropriation and patent infringement case. Jaguar Health, Inc JAGX-43.9%Get Free Report was down, falling 44% to $0.1457 after the company announced a 1-for-60 reverse stock split. Also Check This Out: This Analyst With 85% Accuracy Rate Sees Around 8% Upside In NVIDIA – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts In commodity news, oil traded down 0.4% to $79.74 while gold traded up 0.8% at $2,436.90. Silver traded up 1.9% to $31.84 on Monday, while copper rose 0.7% to $5.0860. European shares were higher today. The eurozone's STOXX 600 gained 0.2%, Germany's DAX rose 0.4% and France's CAC 40 climbed 0.5%. Spain's IBEX 35 Index rose 0.2%, while London's FTSE 100 rose 0.3%. Spain’s consumer confidence indicator climbed to 84.5 in April compared to 82.5 in March. The construction output in Italy rose by 3.8% year-over-year in March. Asian markets closed higher on Monday, with Japan's Nikkei gaining 0.73%, China's Composite Index climbing 0.54%, Hong Kong's Hang Seng Index gaining 0.42% and India's S&P BSE Sensex gaining 0.46%. Hong Kong's unemployment rate came in unchanged at 3% in the three months ending April 2024. Malaysia’s trade surplus shrank to MYR 7.7 billion in April from MYR 12.6 billion in the year-ago month. The People’s Bank of China held key lending rates at the recent fixing. No major economic reports will be released today. Now Read This: Insiders Buying Sempra And 2 Other Stocks
- 05/20/2024
|
Why Is Jaguar Health (JAGX) Stock Down 40% Today?
- Jaguar Health (NASDAQ: JAGX ) stock is falling on Monday as the company prepares for a reverse stock split later this week. Jaguar Health is going to enact a one-for-60 reverse stock split on Thursday.
- 05/20/2024
|
Jaguar Health, Inc. Announces Reverse Stock Split
- Reverse split approved at April 2024 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-60, on Thursday, May 23, 2024 (the "Effective Date") in order to support the Company's compliance with Nasdaq's listing standards. The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX".
- 05/17/2024
|
Jaguar Health Reports First Quarter 2024 Financial Results
- The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 million Top line results expected to be imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product REMINDER: Jaguar to host investor webcast Tuesday, May 14th at 8:30 a.m. Eastern regarding Q1 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated first-quarter 2024 financial results and provided Company updates.
- 05/14/2024
|
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
- Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Tuesday, May 14, 2024 at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates.
- 05/13/2024
|
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
- Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family companies Napo Pharmaceuticals ("Napo") and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German health authorities to initiate a phase 2 clinical trial of Jaguar's novel plant-based prescription drug crofelemer for treatment of short bowel syndrome (SBS) with intestinal failure in adults. Napo Therapeutics has also submitted a CTA to AIFA, the Italian health authority, for the conduct of a clinical trial in pediatric patients with microvillus inclusion disease (MVID), and the approval request process is also underway for this trial in the United Arab Emirates with Dubai Health.
- 05/09/2024
|
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
- Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, May 14, 2024, at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates.
- 05/08/2024
|
Want $10,000? Invest $1,000 in These 3 Penny Stocks Now
- There's the age-old adage, “You have to spend money to make money.” But then again, what if you could spend pennies and get back dollars?
- 05/07/2024
|
Crofelemer, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company's Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
- Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved anti-secretory agents to treat canine diarrhea SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has established a new Investigational New Animal Drug (INAD) file with the Center for Veterinary Medicine (CVM) of the U.S. Food and Drug Administration (FDA) for the company's novel plant-based prescription drug crofelemer to treat general, non-infectious diarrhea in dogs. Crofelemer delayed-release tablets, under the name Canalevia®-CA1, received conditional approval in December 2021 from the FDA for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
- 05/06/2024
|
Here are the moves to make to counter range-bound, choppy markets, says Goldman Sachs
- Friday stock-index futures are looking chipper, given an extra boost by a nonfarm payrolls report that pointed to a cooling labor market and lower wage inflation.
- 05/03/2024
|
Investing in Tech Penny Stocks Right Now, 3 Tips
- Investing in tech penny stocks presents an exciting opportunity for investors looking to expand their portfolios with potentially high-reward options. Penny stocks are typically shares of small companies traded at low prices, often under $5.
- 05/01/2024
|
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
- Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal failure Proof-of-concept studies of crofelemer for MVID and SBS planned for 2024 SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2024 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a Bronze Sponsor of the 10th Annual Elite Ped-GI Congress, which takes place May 2-4, 2024 in Abu Dhabi in the United Arab Emirates (UAE). Additionally, at the conference Napo is sponsoring a panel discussion titled "Masterclass in Congenital Diarrhea" which will focus on microvillus inclusion disease (MVID), an ultra-rare congenital diarrheal disorder.
- 04/29/2024
|
3 Obstacles Investors Face When Buying Penny Stocks
- Penny stocks represent a unique opportunity for investors aiming to expand their portfolios without a significant initial investment. Trading penny stocks can yield high returns due to their low purchase price, making them an appealing option for both seasoned traders and newcomers to the stock market.
- 04/23/2024
|
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care
- Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called “chemo mouth”) in Q3 2024 Company to feature “ Make Cancer Less Shitty ” patient advocacy program at ONS Congress SAN FRANCISCO, CA / ACCESSWIRE / April 22, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") is exhibiting at the Oncology Nursing Society (ONS) Congress taking place April 24-28, 2024 in Washington, DC. "We look forward to driving awareness among the oncology nursing community at this event about Jaguar's expanding focus on cancer supportive care," said Lisa Conte, Jaguar's president and CEO.
- 04/22/2024
|
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
- Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine Miller Collis to the role of Senior Vice President of Growth Strategy. "Cathy Collis was instrumental in bringing about the Gelclair in-license agreement.
- 04/18/2024
|
Why Is Jaguar Health (JAGX) Stock Up 44% Today?
- Jaguar Health (NASDAQ: JAGX ) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new license for a chemo mouth treatment. Jaguar Health is looking to treat chemo mouth, a side effect of chemotherapy, with Gelclair.
- 04/16/2024
|
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
- Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC ("Venture Life"), an international consumer health company focused on the global self-care market, for Venture Life's FDA-approved oral mucositis prescription product, Gelclair, for the U.S. market. "We are very happy to have executed the in-license agreement for Gelclair - and thus to have initiated Jaguar's commercial footprint in our core focus area of cancer supportive care," said Lisa Conte, Jaguar's president and CEO.
- 04/16/2024
|
What Is Going on With Jaguar Health (JAGX) Stock Today?
- Former meme stock Jaguar Health (NASDAQ: JAGX ) has won the approval of certain measures meant to help maintain its Nasdaq listing. These include an extension to Aug. 13 to regain compliance by getting its price over $1 as well as JAGX stockholder approval of a potential reverse stock split.
- 04/10/2024
|
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
- Company not implementing a reverse split at this time Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on April 9, 2024 (the "Special Meeting"). Four proposals were submitted to and approved by the stockholders of the Company at the Special Meeting.
- 04/09/2024
|
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
- Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on April 5, 2024 the Company received formal notice that the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") has granted Jaguar an additional grace period, through August 13, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. To evidence compliance, the Company must report a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days on or before August 13, 2024.
- 04/08/2024
|
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
- Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S. Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium price SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International. A European pharmaceutical industry leader and entrepreneur with more than 35 years' experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, Dr. Radaelli is a member of the board of directors of Napo Therapeutics, the Jaguar family company established in Italy in 2021 that focuses on expanding crofelemer access in Europe, and temporarily served as Napo Therapeutics' Interim Executive Director.
- 04/02/2024
|
Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript
- Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript
- 04/01/2024
|
Jaguar Health Reports 2023 Financial Results
- Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18% Net Q4 2023 revenue of approximately $2.3 million decreased 18% versus net Q3 2023 revenue of $2.8 million and decreased approximately 30% versus net Q4 2022 revenue of $3.3 million Top line results expected forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea REMINDER: Jaguar to host investor webcast Monday, April 1st at 8:30 a.m. Eastern regarding Q4 2023 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / April 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2023.
- 04/01/2024
|
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
- Click here to register for April 1 investor webcast Company plans to file its Earnings Report on April 1, 2024 on Form 10-K for the year ended December 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, April 1, 2024 at 8:30 a.m. Eastern Standard Time to review fourth-quarter 2024 financials and provide corporate updates.
- 03/27/2024
|
Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
- SAN FRANCISCO, CA / ACCESSWIRE / January 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on January 31, 2024 at The Microcap Conference in Atlantic City, New Jersey and participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024. Participation Instructions for Jaguar Health's Presentation at The Microcap Conference When: Wednesday, January 31, 2024 from 10:25-10:45 AM Eastern Standard Time in Track 1 Where: The Microcap Conference is taking place at Caesars Atlantic City Hotel & Casino, 2100 Pacific Avenue, Atlantic City, New Jersey.
- 01/29/2024
|
Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
- Top line data for Jaguar Health's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcoming SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on December 5, 2023 at the MedInvest Oncology Investor Conference. Participation Instructions for Jaguar Health's Virtual Presentation at the MedInvest Oncology Investor Conference When: Tuesday, December 5, 2023 from 9:55 AM - 10:10 AM Pacific Standard Time Registration link for presentation: Click Here About the Phase 3 OnTarget Clinical Trial The OnTarget trial is evaluating the company's plant-based prescription drug crofelemer for prophylaxis (prevention) of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy - an indication Napo also refers to as preventive treatment of chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as chronic debilitating diarrhea (loose and/or watery stools), urgency, and bowel incontinence.
- 11/30/2023
|
Jaguar Health's stock drops after results supporting ‘paramount' trial have not been received yet
- Shares of Jaguar Health Inc. JAGX were mauled for a 21.2% loss in morning trading Tuesday, after the drug maker said it has not yet received data supporting the Phase 3 trial of its treatment of diarrhea in cancer patients receiving therapy. The company is awaiting results from its Good Clinical Practice vendors supporting the trial.
- 11/21/2023
|
Jaguar Health, Inc. (JAGX) Q3 2023 Earnings Call Transcript
- Jaguar Health, Inc. (JAGX) Q3 2023 Earnings Call Transcript
- 11/14/2023
|
Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates
- Click here to register for November 14 investor webcast Company plans to file its Earnings Report on November 14, 2023 on Form 10-Q for the quarter ended September 30, 2023 REMINDER: Jaguar to host virtual educational webinar on rare intestinal failure diseases with leading gastroenterologists and nutrition experts November 8, 2023 from 1:00 PM to 2:30 PM Eastern; Click here to register for webinar SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, November 14, 2023 at 8:30 a.m. Eastern Standard Time to review third-quarter 2023 financials and provide corporate updates.
- 11/08/2023
|
Jaguar Health to Present November 1st at Emerging Growth Conference
- Individual and institutional investors as well as advisors, analysts, and members of the financial media are invited to attend Jaguar's real-time interactive presentation SAN FRANCISCO, CA / ACCESSWIRE / October 26, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, is presenting virtually at the Emerging Growth Conference on Wednesday, November 1, 2023 from 12:00 p.m. - 12:30 p.m.
- 10/26/2023
|
Napo Pharmaceuticals, a Jaguar Health Family Company, Accepted to Present Results of Its Pivotal Phase 3 OnTarget Study for Preventive Treatment of Cancer Therapy-Related Diarrhea December 7th at the San Antonio Breast Cancer Symposium
- Top line results of this pivotal trial expected before Thanksgiving More than 1 million cancer patients in the US receive chemotherapy or radiation each year, according to the CDC, and cancer patients with diarrhea are 40% more likely to discontinue their targeted therapy SAN FRANCISCO, CA / ACCESSWIRE / October 25, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that on December 7, 2023, the company will present results from its pivotal Phase 3 OnTarget study of Napo's plant-based prescription drug crofelemer under investigation for the prophylaxis (prevention) of diarrhea associated with targeted cancer therapies used to treat solid tumors at the San Antonio Breast Cancer Symposium (SABCS). Napo expects to announce top line results of the trial by the Thanksgiving holiday.
- 10/25/2023
|
Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor Forum
- Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE / October 12, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present and host one-on-one meetings with investors during the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023, and on October 18, 2023 at the in-person BIO Investor Forum. Participation Instructions for Jaguar Health Presentation at the Lytham Partners Fall 2023 Investor Conference Company Webcast: Jaguar Health's webcast presentation will be available for viewing at 7:00 AM Eastern on Tuesday, October 17, 2023, at https://wsw.com/webcast/lytham9/jagx/2033040.
- 10/12/2023
|
Jaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor Conference
- Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE / September 28, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will present at the LD Micro Main Event investor conference on October 3, 2023, and at the Global Capital Network Investor Conference on October 5, 2023. Participation Instructions for Jaguar Presentation at LD Micro Main Event When: Tuesday, October 3, 2023 from 12:00-12:25 PM Pacific Daylight Time in Track 3 Where: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049 Registration link for conference: Click Here Participation Instructions for Jaguar Presentation at Global Capital Network Investor Conference When: Thursday, October 5, 2023 during the MedTech segment of the conference Where: Newport Beach Hyatt, 1107 Jamboree, Newport Beach, CA 92660 Registration link for conference: Click Here As recently announced by Napo Pharmaceuticals (Napo), a Jaguar family company, the last patient has completed their final visit for the stage 1 primary endpoint treatment period of Napo's pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy.
- 09/28/2023
|
Filament Health's Magdalena Biosciences JV with Jaguar Health completes import of coca leaf from Peru
- Filament Health Corp (OTCQB:FLHLF) told investors that its Magdalena Biosciences joint venture (JV) with Jaguar Health has completed an import of coca leaf to Filament's Metro Vancouver research and development facility. The clinical-stage natural psychedelic drug development said its wholly-owned subsidiary Psilo Scientific received the imported leaves, which will be used for initial research purposes to look at neuropsychiatric indications.
- 09/20/2023
|
Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
- Click here to access webcast replay Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE / September 14, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal (GI) prescription medicines, today announced that the recording of the company's virtual presentation at the September 11-13, 2023 H.C. Wainwright 25th Annual Global Investment Conference can be accessed by clicking here.
- 09/14/2023
|
Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
- Napo Pharmaceuticals, a Jaguar family company, reported completion August 17 of last patient last visit for its pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 28, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's president, founder, and CEO, will present virtually at the Emerging Growth Conference September 7, 2023 and virtually at the September 11-13, 2023 H.C. Wainwright 25th Annual Global Investment Conference.
- 08/28/2023
|
Jaguar Health, Inc. (JAGX) Q2 2023 Earnings Call Transcript
- Jaguar Health, Inc. (NASDAQ:JAGX ) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET Company Participants Lisa Conte - President and Chief Executive Officer Carol Lizak - Chief Financial Officer Operator Good morning. Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, and product initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements.
- 08/14/2023
|
Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
- Click here to register for webcast Company plans to file its Earnings Report on August 14, 2023 on Form 10-Q for the quarter ended June 30, 2023 SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, August 14, 2023 at 8:30 a.m. Eastern Daylight Time to review second-quarter 2023 financials and provide corporate updates.
- 08/10/2023
|
Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC
- SAN FRANCISCO, CA / ACCESSWIRE / August 3, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, is presenting at an invitation-only lunch gathering of the Wall Street Wonders Investment Group in New York City at 1:30 p.m. EDT on Friday August 4, 2023.
- 08/03/2023
|
Jaguar Health to Present June 21st at MedInvest Oncology Investor Conference
- Reminder: Ladenburg Thalmann to host virtual discussion June 22, 2023 at 1:00 PM EDT with Jaguar CEO and leading patient advocates on impact of cancer therapy-related diarrhea on patients & importance of the patient voice in supportive care; Click here to register for event Jaguar recently completed patient enrollment in its ongoing pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / June 15, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that at 6 p.m. EDT on Wednesday, June 21, 2023, Lisa Conte, Jaguar's president, founder, and CEO, will present virtually at the MedInvest Oncology Investor Conference and will be available to participate in virtual one-on-one meetings during the event.
- 06/15/2023
|
Jaguar Animal Health, Inc. (JAGX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
- After losing some value lately, a hammer chart pattern has been formed for Jaguar Animal Health, Inc. (JAGX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 06/13/2023
|
Jaguar Health to Present at Lytham Partners Spring 2023 Investor Conference & Participate in Animal Health Panel
- Jaguar Animal Health's Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive FDA conditional approval and is widely available through prominent pet retailers in the U.S. SAN FRANCISCO, CA / ACCESSWIRE / May 16, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on Thursday, May 18, 2023 Lisa Conte, Jaguar's president, founder, and CEO, will present at the virtual Lytham Partners Spring 2023 Investor Conference and take part in an Animal Health Panel Discussion during the event. Company Webcast The Company's webcast presentation will be available for online viewing at 9:00 a.m.
- 05/16/2023
|
REMINDER: Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates
- Click here to register for webcast Company plans to file its Earnings Report on May 15, 2023 on Form 10-Q for the quarter ended March 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Monday, May 15, 2023 at 8:30 a.m. Eastern Daylight Time to review first-quarter 2023 financials and provide corporate updates.
- 05/12/2023
|
How to Use Social Media to Make Money Trading Penny Stocks
- Use these tips to utilize social media for trading penny stocks The post How to Use Social Media to Make Money Trading Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/12/2023
|
Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates
- Click here to register for webcast Company plans to file its Earnings Report on May 15, 2023 on Form 10-Q for the quarter ended March 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, May 15, 2023 at 8:30 a.m. Eastern Daylight Time to review first-quarter 2023 financials and provide corporate updates.
- 05/08/2023
|
Jaguar Health, Inc. (JAGX) Q4 2022 Earnings Call Transcript
- Jaguar Health, Inc. (NASDAQ:JAGX ) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ET Company Participants Lisa Conte - President & Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Good morning. Before I turn the call over to management, I would like to remind you that management may make forward-looking statements relating to such matters as contained growth prospects for the company, uncertainties regarding market acceptance of products and the impact of competitive products and pricing, industry trends and product initiatives, including projects in the development stage which may not achieve scientific objectives or be stringent regulatory requirements.
- 03/27/2023
|
Jaguar Health Announces Time Change for March 27th Investor Webcast to 8:00 AM EDT
- Click here to register for webcast Company plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / March 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company investor webcast scheduled for Monday, March 27, 2023 to review fourth-quarter 2022 financials and provide corporate updates will now take place at 8:00 a.m. Eastern Daylight Time instead of 8:30 a.m.
- 03/24/2023
|
Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates
- Click here to register for webcast Company plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / March 21, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, March 27, 2023 at 8:30 a.m. Eastern Daylight Time to review fourth-quarter 2022 financials and provide corporate updates.
- 03/21/2023
|
Jaguar Health to Present at BioTrinity 2023 Conference's R&D Spotlight on Rare Diseases
- Presentation will cover Jaguar and Napo Therapeutics' focus on development and commercialization of crofelemer for short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) Crofelemer has received orphan drug designation from the FDA and the European Medicines Agency for both SBS and a specific genetic abnormality resulting in a CDD condition SAN FRANCISO, CA / ACCESSWIRE / March 2, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Lisa Conte, the Company's founder, president, and CEO, is scheduled to present at the BioTrinity 2023 conference in London on Tuesday, April 25, 2023 during the R&D Spotlight session on Rare Diseases. Ms. Conte is also Chairman of the Board of Napo Therapeutics, the corporation Jaguar established in Italy in 2021 with a mission to expand crofelemer access in Europe for the treatment and management of targeted orphan and rare disease indications.
- 03/02/2023
|
7 F-Rated Stocks to Sell in February
- We're out of January and finally settling into the 2023 year. After ending 2022 in the red, all the major indices are showing gains through the first month of the year.
- 02/03/2023
|
Is Jaguar Health (JAGX) Stock Really Up 6,800%?
- Jaguar Health (NASDAQ: JAGX ) stock is on the move Monday as investors seek answers to its massive 6,800% gain this morning. For the record, JAGX stock didn't actually rally almost 7,000% in Monday morning trading.
- 01/23/2023
|
Jaguar Health to Present at Lytham Partners Investor Select Conference on January 31st
- SAN FRANCISCO, CA / ACCESSWIRE / January 20, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on Tuesday, January 31, 2023 Lisa Conte, Jaguar's president, founder, and CEO, will present at the virtual Lytham Partners Investor Select Conference. Company Webcast The Company's webcast presentation will be available for online viewing at 9:00 a.m.
- 01/20/2023
|
Are Biotech Penny Stocks Worth Buying? 3 Tips
- Use these tips for buying biotech penny stocks in 2022 The post Are Biotech Penny Stocks Worth Buying? 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/12/2023
|
REMINDER: Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar's Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from Psychoactive Plants
- The webcast will include: Commentary from leading breast cancer medical oncologist and hematologist Lee Schwartzberg, MD, FACP on the unmet need for a focused and biological approach to the management of cancer therapy-related diarrhea A presentation by ethnobotanist, anthropologist, bestselling author and former National Geographic Explorer-in-Residence Dr. Wade Davis about the history and traditional uses of psychoactive plants and their potential to treat unmet mental health needs Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / January 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that the company will conduct an investor webcast tomorrow, Thursday, January 12, 2023, at 10:30 a.m. Eastern Standard Time to highlight the high unmet need associated with cancer therapy-related diarrhea (CTD).
- 01/11/2023
|
Dear JAGX Stock Fans, Mark Your Calendars for Jan. 12
- Fans of Jaguar Health (NASDAQ: JAGX ) stock will want to keep an eye on the company tomorrow as it prepares for an investor webcast. Investors will want to tune into that webcast as it will cover topics relevant to the company.
- 01/11/2023
|
Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar's Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from Psychoactive Plants
- The webcast will include: Commentary from leading breast cancer medical oncologist and hematologist Lee Schwartzberg, MD, FACP on the unmet need for a focused and biological approach to the management of cancer therapy-related diarrhea A presentation by ethnobotanist, anthropologist, bestselling author and former National Geographic Explorer-in-Residence Dr. Wade Davis about the history and traditional uses of psychoactive plants and their potential to treat unmet mental health needs Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Thursday, January 12, 2023 at 10:30 a.m. Eastern Standard Time to highlight the high unmet need associated with cancer therapy-related diarrhea (CTD).
- 01/10/2023
|
Jaguar Health (JAGX) Q3 2022 Earnings Call Transcript
- Jaguar Health Inc. (NASDAQ:JAGX ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Lisa Conte - President, Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to the matters as contained growth prospects for the company. Uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements, thus forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
- 11/14/2022
|
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th
- Jaguar CEO Lisa Conte Will Also Participate in an Orphan Drug Panel Presentation on September 28th During the Lytham Partners Fall 2022 Investor Conference SAN FRANCISCO, CA / ACCESSWIRE / September 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on September 28, 2022 Lisa Conte, Jaguar's president, founder, and CEO, will present at the virtual Lytham Partners Fall 2022 Investor Conference in addition to participating in a panel presentation titled "Orphan Drugs: Innovative Companies Addressing Rare Diseases" at the conference. Additionally, Conte will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022.
- 09/22/2022
|
Jaguar Health, Inc.'s (JAGX) CEO Lisa Conte on Q2 2022 Results - Earnings Call Transcript
- Jaguar Health, Inc. (NASDAQ:JAGX ) Q2 2022 Earnings Conference Call August 22, 2022 8:30 AM ET Company Participants Lisa Conte - Founder, President, and Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive product and pricing, industry trends and product initiatives including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
- 08/22/2022
|
Jaguar Health to Host Investor Webcast Monday, August 22nd at 8:30 AM Eastern Time Regarding Q2 2022 Financials & Corporate Updates
- Click here to register for webcast Company plans to file its Earnings Report on August 22, 2022 on Form 10-Q for the quarter ended June 30, 2022 SAN FRANCISCO, CA / ACCESSWIRE / August 17, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Monday, August 22, 2022, at 8:30 a.m. Eastern Time to review second-quarter 2022 financials and provide corporate updates.
- 08/17/2022
|
Penny Stocks, Market Trends in July 2022
- Are these market trends part of your penny stocks trading strategy? The post Penny Stocks, Market Trends in July 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/09/2022
|
What to Know About Buying Penny Stocks on June 30th
- Here's what you need to know about buying penny stocks on June 29th The post What to Know About Buying Penny Stocks on June 30th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/30/2022
|
Hot Penny Stocks to Buy Right Now? Check These 3 Out
- Can these penny stocks make gains this coming week? The post Hot Penny Stocks to Buy Right Now?
- 06/24/2022
|
Penny Stocks To Buy Now? 4 To Watch Under $1
- Penny stocks under $1 to watch right now. The post Penny Stocks To Buy Now?
- 05/23/2022
|
UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates
- Click here to register for webcast Company plans to file its Earnings Report on May 10, 2022 on Form 10-Q for the quarter ended March 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Tuesday, May 10, 2022, at 8:30 a.m. Eastern Time to review first-quarter 2022 financials and provide corporate updates.
- 05/05/2022
|
Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates
- Click here to register for webcast Company plans to file its Earnings Report on May 10, 2022 on Form 10-Q for the quarter ended March 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Tuesday, March 10, 2022, at 8:30 a.m. Eastern Time to review first-quarter 2022 financials and provide corporate updates.
- 05/05/2022
|
Here's Why Jaguar Health Shares Are Rising
- Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 10.90% at $0.70 on continued momentum after the company last week announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and distribution rights for specified human indications of crofelemer.
- 04/04/2022
|
Are Penny Stocks Worth Investing In This Month? 3 To Watch Under $1
- Check these 3 penny stocks out for your watchlist this month The post Are Penny Stocks Worth Investing In This Month? 3 To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/03/2022
|
Best Penny Stocks to Buy as March Comes to an End? 3 to Check Out
- Which penny stocks are you watching in April? The post Best Penny Stocks to Buy as March Comes to an End?
- 03/31/2022
|
Here's Why Jaguar Health Shares Are Popping Off
- Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 31.2% at $0.70 after the company announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and distribution rights for specified human indications of crofelemer in the Middle East. Per.
- 03/31/2022
|
Why Is Jaguar Health (JAGX) Stock Up Today?
- Here's the big partnership news that's taking shares of Jaguar Health and JAGX stock soaring in afternoon trading today. The post Why Is Jaguar Health (JAGX) Stock Up Today?
- 03/31/2022
|
Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q4 2021 Results - Earnings Call Transcript
- Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q4 2021 Results - Earnings Call Transcript
- 03/14/2022
|
Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast
- Click here to access webcast replay Core 2022 development initiatives: Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) Initiation and completion in 2H 2022 of investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome with intestinal failure (SBS-IF) FDA conditional approval in December 2021 of Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea (CID) in dogs Fourth quarter 2021 Mytesi net revenue was approximately $2.1 million versus approximately $0.6 million in the third quarter of 2021, an increase of 230% SAN FRANCISCO, CA / ACCESSWIRE / March 14, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the recording of the company's March 14, 2022, investor webcast regarding company updates and reported consolidated financial results for the year ended December 31, 2021 can be accessed by clicking here . About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals, & Napo Therapeutics Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea.
- 03/14/2022
|
5 Penny Stocks Under $1 To Buy According To Redditors This Week
- Reddit penny stocks under $1 to watch this week. The post 5 Penny Stocks Under $1 To Buy According To Redditors This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/14/2022
|
Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates
- Click here to register for webcast Company plans to file its Annual Report on March 11, 2022 on Form 10-K for the fiscal year ended December 31, 2021 SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Monday, March 14, 2022, at 8:30 a.m. Eastern Time to review fourth-quarter 2021 financials and provide corporate updates.
- 03/07/2022
|
3 Penny Stocks to Watch Under $1 Right Now
- Check these three under $1 penny stocks out for your watchlist The post 3 Penny Stocks to Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/12/2022
|
Why Jaguar Health Shares Are Rising
- Jaguar Health Inc (NASDAQ:JAGX) shares are trading higher following a Tuesday 13G filing from Oasis Capital showing a 9.99% stake in the company. According to the filing, Oasis Capital has a passive stake of 4,604,484 shares in Jaguar Health.
- 01/12/2022
|
Jaguar Health Stock (JAGX): Why The Price Surged
- The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by 20% in the most recent trading session. This is why it happened.
- 12/22/2021
|
FDA Approves Jaguar Health's Plant-Based Therapy For Chemo-Induced Diarrhea In Dogs
- The FDA has granted conditional approval for Jaguar Health Inc's (NASDAQ: JAGX) Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced diarrhea (CID) in dogs. This is the first and only product indicated for treating chemotherapy-induced diarrhea (CID) in dogs to receive any approval from the FDA.
- 12/22/2021
|
JAGX Stock Alert: 5 Things to Know About the News Sending Jaguar Health Higher
- Shares of JAGX stock are flying higher after the FDA granted conditional approval for its chemotherapy-induced diarrhea treatment. The post JAGX Stock Alert: 5 Things to Know About the News Sending Jaguar Health Higher appeared first on InvestorPlace.
- 12/21/2021
|
Trending Penny Stocks to Buy Today? 3 For Your Watchlist
- Which penny stocks are you watching right now? The post Trending Penny Stocks to Buy Today?
- 12/21/2021
|
Top Penny Stocks to Add to Your Watchlist As 2021 Ends
- With 2021 coming to an end, which penny stocks are you watching? The post Top Penny Stocks to Add to Your Watchlist As 2021 Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/09/2021
|
Jaguar Health Stock (JAGX): Why The Price Increased This Week
- The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by over 8% this week. This is why it happened.
- 12/09/2021
|
9 Psychedelic Stocks to Watch For 2022
- The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.
- 12/06/2021
|
Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients
- Jaguar Health Inc (NASDAQ: JAGX) announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating crofelemer to prevent chemotherapy-induced diarrhea (CID). The trial included HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab, and a taxane.
- 11/19/2021
|
Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q3 2021 Results - Earnings Call Transcript
- Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q3 2021 Results - Earnings Call Transcript
- 11/17/2021
|
Jaguar Health: Q3 Earnings Insights
- Jaguar Health (NASDAQ:JAGX) reported its Q3 earnings results on Wednesday, November 17, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
- 11/17/2021
|
Jaguar Health's Earnings Outlook
- Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Wednesday, 2021-11-17. Here's what investors need to know before the announcement.
- 11/16/2021
|
Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time
- Click here to register for webcast Company plans to file Q3 2021 10-Q on November 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company's investor webcast to review third-quarter 2021 financials and provide business updates will take place at 8:30 a.m. Eastern Time on Wednesday, November 17, 2021 instead of today.
- 11/15/2021
|
Earnings Preview: Jaguar Health
- Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.
- 11/12/2021
|
Jaguar Health to Host Investor Webcast Monday, November 15th at 8:30 AM Eastern Time Regarding Q3 2021 Financials & Business Updates
- Click here to register for webcast Company plans to file Q3 2021 10-Q on November 15, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host a webcast on Monday, November 15, 2021 at 8:30 a.m. Eastern Time to review third-quarter 2021 financials and provide business updates.
- 11/10/2021
|
Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.
- Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger Results accepted for third-party, investigator-initiated Phase 2 HALT-D study evaluating crofelemer for prevention and prophylaxis of diarrhea in breast cancer patients as a poster for December 2021 San Antonio Breast Cancer Symposium SAN FRANCISCO, CA / ACCESSWIRE / October 7, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) provided updates today regarding ongoing research and development related to the company's crofelemer drug product candidates, and also announced that Dragon SPAC S.p.A. and Napo EU S.p.A.
- 10/07/2021
|
Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award
- Award celebrates Ms. Conte's 30-year, unrelenting commitment to supporting Indigenous communities in the Amazon and responsibly harvesting and commercializing the first-ever plant-based oral medicine approved under FDA Botanical Guidance SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Pure Earth, an international non-profit organization that is a leader in the global fight to reduce disease-causing pollution, is awarding Jaguar's Founder, President, and Chief Executive Officer Lisa Conte with an Impact Award.
- 09/30/2021
|
Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021
- Leading oncologists discuss importance of supportive care for cancer patients to address debilitating diarrhea resulting from cancer therapy Virtual event 1:00 PM to 2:10 PM Eastern Registration open now for financial and business community; Click here to register SAN FRANCISCO, CA / ACCESSWIRE / September 27, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Ladenburg Thalmann is hosting an R&D Showcase webinar about cancer therapy-related diarrhea (CTD) on September 29, 2021 from 1:00 p.m. to 2:10 p.m.
- 09/27/2021
|
Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs
- Jaguar planning for launch of Canalevia™ for CID in dogs this December Canalevia is the first and only oral plant-based prescription drug candidate for CID in dogs SAN FRANCISCO, CA / ACCESSWIRE / September 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it was informed on September 21, 2021 by the FDA's Center for Veterinary Medicine (CVM) that the Target Animal Safety (TAS) technical section of the company's application for conditional approval of Canalevia for chemotherapy-induced diarrhea (CID) under the Minor Use/Minor Species (MUMS) section of The Minor Use and Minor Species Animal Health Act of 2004 has been deemed "Complete". The TAS section - the last of the four major technical sections of Jaguar's application - describes testing undertaken to show that a drug candidate is safe for use under the conditions for which the drug will be prescribed following its approval.
- 09/23/2021
|
REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time
- Click here to register for webcast Jaguar kicks off educational awareness contest in honor of Indigenous Peoples' Day; Click here to enter SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host a webcast on Monday, September 20, 2021 at 8:30 a.m. Eastern Time.
- 09/16/2021
|
Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency
- The conditional marketing authorization pathway in Europe for crofelemer for this orphan disease is the initial focus of Napo EU under the license agreement between Napo EU and Napo Pharmaceuticals Jaguar to host investor webcast Monday, September 20th at 8:30 a.m. Eastern; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / September 15, 2021 / Jaguar Health (NASDAQ:JAGX) today announced that the European Medicines Agency (EMA) has confirmed that the Orphan Drug Designation (ODD) application for crofelemer submitted by Napo EU S.p.A.
- 09/15/2021
|
Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market
- Participating investors include Jaguar CEO and CFO, Dragon SPAC S.p.A. sponsor Josh Mailman, and plant-based pharmaceutical manufacturing pioneer Indena S.p.A.
- 09/14/2021
|
3 Top Penny Stocks That You Need to Know About Right Now
- As September turns bullish for penny stocks, which small-caps are on your watchlist? The post 3 Top Penny Stocks That You Need to Know About Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/10/2021
|
JAGX Stock: What Is Going on With Jaguar Health Today?
- Today, JAGX stock is surging higher on news of executive appointments, as well as the company's recent reverse stock split. The post JAGX Stock: What Is Going on With Jaguar Health Today?
- 09/09/2021
|
Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director
- Appointments represent Jaguar's focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization of crofelemer prescription product for chemotherapy-induced diarrhea in dogs Company to host investor webcast Monday, September 20th at 8:30 a.m. Eastern; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / September 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the appointment of Karen J.
- 09/09/2021
|
Hot Penny Stocks That Top Investors Are Watching Right Now
- Why top penny stock investors are watching these hot small-caps right now The post Hot Penny Stocks That Top Investors Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/08/2021
|
JAGX Stock: 1-For-3 Reverse Split Goes Into Effect
- Jaguar Health, Inc. (NASDAQ:JAGX) had recently announced a 1-for-3 reverse stock split, which has now gone into effect. These are the details.
- 09/08/2021
|
Jaguar Health Stock Is Trading Lower In Reaction To Reverse Stock Split
- Jaguar Health Inc (NASDAQ: JAGX) will effect a reverse stock split of its issued and outstanding voting common stock at an exchange ratio of 1-for-3. The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on September 8.
- 09/07/2021
|
Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split
- Reverse split approved by majority of common stock shareholders at December 2020 special meeting of stockholders Shares of Jaguar common stock to begin trading on split-adjusted basis on September 8, 2021 SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-3, on Wednesday, September 8, 2021 (the "Effective Date"). The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX".
- 09/03/2021
|
Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders
- Proposals 1, 2, 4, 5 & 6 approved SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's May 13, 2021 Annual Meeting of Stockholders, which was adjourned until September 3, 2021. Six items of business were addressed at the meeting today: Proposal 1: To elect one Class III director.
- 09/03/2021
|
Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting
- Exploratory study evaluating effects of crofelemer on gut microbiome SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Napo Pharmaceuticals, the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with an exploratory clinical study on the effect of crofelemer (Mytesi®) on the gastrointestinal microbiome in people living with HIV/AIDS (PLWHA) has been submitted for consideration for presentation at IDWeek 2021, which takes place virtually from September 29 to October 3. Mytesi (crofelemer) is an antidiarrheal drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).
- 08/23/2021
|
Best Biotech Penny Stocks to Buy Right Now? 3 to Watch Next Month
- Biotech penny stocks are heating up right now, here's 3 for next month's watchlist The post Best Biotech Penny Stocks to Buy Right Now? 3 to Watch Next Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/20/2021
|
Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe
- Per the terms of the agreement, Napo Pharmaceuticals will receive an upfront payment of $10 million payable in two installments following the anticipated merger of Napo EU and Dragon SPAC S.p.A. and is eligible to receive additional payments related to milestones, royalties, and product transfers Napo EU's initial focus is on accelerated conditional approval for orphan disease: short bowel syndrome with intestinal failure SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Napo Pharmaceuticals, Inc. (Napo), the wholly owned US subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX), today announced the signing of a license agreement with Napo's Italian subsidiary, Napo EU S.p.A.
- 08/19/2021
|
5 Penny Stocks To Buy According To Top Wall Street Analysts In 2021
- Analysts say these are penny stocks to buy. Do you agree?
- 08/18/2021
|
Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea
- In support of planned Investigational New Drug application for lechlemer, Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, received comprehensive animal toxicity preclinical services supported by the National Institute of Allergy and Infectious Diseases for four studies SAN FRANCISCO, CA / ACCESSWIRE / August 17, 2021 / Napo Pharmaceuticals, Inc. ("Napo"), the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), announced today the completion of an additional preclinical toxicology study intended to support continued development of NP-300 (lechlemer) for the symptomatic relief of diarrhea from cholera and other infectious diarrheal conditions. The study findings support the Investigational New Drug (IND) application Napo plans to file for lechlemer for this indication in the first half of 2022.
- 08/17/2021
|
Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q2 2021 Results - Earnings Call Transcript
- Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q2 2021 Results - Earnings Call Transcript
- 08/13/2021
|
Jaguar Health, Inc. Reports 2021 Second Quarter Financial Results
- Second quarter 2021 Mytesi ® net and gross sales were approximately $0.4 million and approximately $4.9 million Company transitioning to primarily selling Mytesi directly through selected specialty pharmacies as part of Company's market access strategy Company to host investor webcast Friday, August 13th at 8:00 a.m. Eastern regarding second quarter 2021 financials & business updates; Webcast registration link appears below SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated second quarter 2021 financial results.
- 08/13/2021
|
Recap: Jaguar Health Q2 Earnings
- Shares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).
- 08/13/2021
|
Jaguar Health Announces Time Change for Friday, August 13th Investor Webcast to 8:00 AM Eastern Time
- Registration link for webcast appears below Company plans to file Q2 2021 10-Q on August 13, 2021 SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company investor webcast scheduled for Friday, August 13, 2021 will take place at 8:00 a.m. Eastern Time instead of 8:30 a.m.
- 08/10/2021
|
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote
- Based on a preliminary review of votes cast, over 75% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene September 3, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum SAN FRANCISCO, CA / ACCESSWIRE / August 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') today announced that it has adjourned its Annual Meeting of Stockholders held on May 13, 2021 (the "Annual Meeting") for a fourth time due to a lack of quorum. The adjourned meeting will be held at 8:30 a.m.
- 08/06/2021
|
REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Interview with Lisa Conte to Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
- Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / July 28, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that an Innovators with Jane King interview of Lisa Conte, the company's founder, president, and CEO, and member of the board of directors of Napo EU S.p.A., will be aired during an investor webcast tomorrow (Thursday, July 29, 2021) at 8:30 AM Eastern to provide business updates for Jaguar, Napo Pharmaceuticals, Inc. (Jaguar's wholly owned subsidiary), and the Italian subsidiary of Napo Pharmaceuticals, Napo EU S.p.A.
- 07/28/2021
|
Jaguar Health Announces that Innovators with Jane King Interview with Lisa Conte will Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
- Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) announced today that an Innovators with Jane King interview of Lisa Conte, the company's founder, president, and CEO, will be aired during an investor webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to provide business updates for Jaguar, Napo Pharmaceuticals, Inc. (Jaguar's wholly owned subsidiary), and the Italian subsidiary of Napo Pharmaceuticals, Napo EU S.p.A., which, with Dragon SPAC S.p.A.
- 07/26/2021
|
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced today that effective July 15, 2021, the Company granted nonstatutory stock options for the purchase of up to 8,000 shares of the Company's common stock to New Employee 1 and nonstatutory stock options for the purchase of up to 8,000 shares of the Company's common stock to New Employee 2. These nonstatutory stock options have an exercise price of $1.41 per share, representing the closing price of Jaguar's common stock as reported by Nasdaq on the grant date.
- 07/23/2021
|
Could These Biotech Penny Stocks Explode in August 2021?
- Why these biotech penny stocks are seeing heightened momentum right now The post Could These Biotech Penny Stocks Explode in August 2021? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/22/2021
|
4 Stocks To Watch With The Stock Market Down Today
- Which Penny Stocks Are Investors Watching After the Stock Market Crash? The post 4 Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/19/2021
|
Napo EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A.
- Napo EU, the identified target of Dragon SPAC, seeks to develop plant-based crofelemer to potentially treat orphan disease - short bowel syndrome (crofelemer has received orphan-drug designation from the US FDA for SBS) Merger of Napo EU & Dragon SPAC expected to be effective within approximately 80 days, with related future SBS license and milestone fees totaling up to $12.5 million MILAN, ITALY and SAN FRANCISCO, CA / ACCESSWIRE / July 19, 2021 / Dragon SPAC S.p.A. and Napo EU S.p.A.
- 07/19/2021
|
4 Penny Stocks That Are Worth Adding to Your Watchlist in July
- Are These Penny Stocks Worth Adding to Your Watchlist in July 2021? The post 4 Penny Stocks That Are Worth Adding to Your Watchlist in July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/16/2021
|
Jaguar Health Announces Completion of Investigator-Initiated Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients
- Abstract of study results submitted by the third-party investigators to December 2021 San Antonio Breast Cancer Symposium SAN FRANCISCO, CA / ACCESSWIRE / July 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the third-party, investigator-initiated Phase 2 HALT-D study evaluating the effectiveness of Mytesi® (crofelemer) for symptomatic relief of diarrhea in HER2 positive breast cancer patients receiving chemotherapy with trastuzumab, pertuzumab, and docetaxel or paclitaxel or trastuzumab, pertuzumab, carboplatin, and docetaxel has been completed. The investigators of the study, which was sponsored by Georgetown University and funded by Genentech, a member of the Roche Group, have submitted an abstract of the results to the San Antonio Breast Cancer Symposium for consideration for presentation at its December 7-10, 2021 event.
- 07/14/2021
|
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, August 6, 2021 and Encourages All Shareholders to Vote
- Based on a preliminary review of votes cast, over 74% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene August 6, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum SAN FRANCISCO, CA / ACCESSWIRE / July 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') today announced that it has adjourned its Annual Meeting of Stockholders held on May 13, 2021 (the "Annual Meeting") for a third time due to a lack of quorum. The adjourned meeting will be held at 8:30 a.m.
- 07/09/2021
|
Top Penny Stocks to for Your Buy List Right Now? Here's 9 to Watch
- Are these top penny stocks on your watchlist right now? The post Top Penny Stocks to for Your Buy List Right Now?
- 07/07/2021
|
Best Reddit Penny Stocks to Buy Now? 7 for Your July Small-Caps List
- Are these Reddit penny stocks the best 7 to watch in July 2021? The post Best Reddit Penny Stocks to Buy Now?
- 07/07/2021
|
JAGX Stock: The New Analyst Price Target Making Jaguar Health Jump Today
- Jaguar Health (JAGX) stock is jumping higher on Wednesday after an analyst initiated coverage of the shares with a positive rating. The post JAGX Stock: The New Analyst Price Target Making Jaguar Health Jump Today appeared first on InvestorPlace.
- 07/07/2021
|
Jaguar Health Stock Increases Over 10% Pre-Market: Why It Happened
- The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by over 10% pre-market. This is why it happened.
- 07/07/2021
|
Best Biotech Penny Stocks In Summer 2021? 7 For Your Watchlist
- Are these the best biotech penny stocks to watch right now? The post Best Biotech Penny Stocks In Summer 2021?
- 07/01/2021
|
Jaguar Health Set to Join Russell Microcap Index
- Jaguar kicks off educational awareness contest about medicinal plants SAN FRANCISCO, CA / ACCESSWIRE / June 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Jaguar is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.
- 06/23/2021
|
8 Penny Stocks in These 3 Industries Have Traders Looking to Buy
- Which industries are investors finding penny stocks in right now? Check these 3 out The post 8 Penny Stocks in These 3 Industries Have Traders Looking to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/21/2021
|
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, July 9, 2021 and Encourages All Shareholders to Vote
- Based on a preliminary review of votes cast, over 76% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene July 9, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum SAN FRANSICO, CA / ACCESSWIRE / June 11, 2021 / Jaguar Health, Inc. (Nasdaq:JAGX) ('Jaguar' or the 'Company') today announced that it has adjourned its Annual Meeting of Stockholders held on May 13, 2021 (the "Annual Meeting") for a second time due to a lack of quorum. The adjourned meeting will be held at 8:30 a.m.
- 06/11/2021
|
Trading Penny Stocks This Summer? Here's 4 You Don't Want to Miss
- 4 penny stocks that investors are watching in Summer 2021 The post Trading Penny Stocks This Summer? Here's 4 You Don't Want to Miss appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/09/2021
|
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, CA / ACCESSWIRE / June 4, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective May 27, 2021, the Company granted nonstatutory stock options for the purchase of up to 225,000 shares of the Company's common stock to a new employee, as an inducement award under the Company's 2020 Inducement Plan. These nonstatutory stock options have an exercise price of $1.68 per share, representing the closing price of Jaguar's common stock as reported by Nasdaq on the grant date.
- 06/04/2021
|
Trading Biotech Penny Stocks? Check These 3 Out
- Biotech penny stocks are heating up as Covid cases decline; which small-caps are on your watchlist? The post Trading Biotech Penny Stocks?
- 06/02/2021
|
REMINDER: Innovators with Jane King Webcast Interview with Jaguar Health CEO Lisa Conte & Dragon SPAC Founding Sponsor Josh Mailman to Take Place Thursday, June 3, 2021 at 8:30 AM Eastern
- Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / June 2, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today that an Innovators with Jane King webcast interview with Jaguar CEO Lisa Conte & Dragon SPAC S.p.A. ("Dragon SPAC") founding sponsor Josh Mailman will air this Thursday, June 3, 2021, at 8:30 AM Eastern Time.
- 06/02/2021
|
Napo EU S.p.A., Jaguar Health's Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU
- Jaguar & Dragon SPAC announce initial funding of $10.8 million into Dragon SPAC Napo EU to focus initially on conditional approval for an important orphan indication, short bowel syndrome (SBS), a condition leading to intestinal failure Innovators with Jane King webcast interview with Jaguar CEO Lisa Conte & Dragon SPAC founding sponsor Josh Mailman to take place Thursday, June 3rd at 8:30 AM Eastern Registration link for webcast appears below Equita Group S.p.A., a leading Italian based investment bank, advising Dragon SPAC; Cantor Fitzgerald & Co. advising Jaguar on non-deal related activities SAN FRANCISCO, CA & MILAN, ITALY / ACCESSWIRE / June 1, 2021 / Napo EU S.p.A.
- 06/01/2021
|
JAGX Stock Price: 11.84% Increase Explanation
- The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by 11.84% today. This is why it happened.
- 05/26/2021
|
JAGX Stock: Why Jaguar Health Is Climbing Higher Today
- Investors in JAGX stock are having a solid week, after the company made a few key announcements that have taken this stock higher. The post JAGX Stock: Why Jaguar Health Is Climbing Higher Today appeared first on InvestorPlace.
- 05/26/2021
|
Penny Stocks Are Heating Up, Here's 3 You Need to Know About
- Are these the best penny stocks to watch right now? Take a look and decide for yourself The post Penny Stocks Are Heating Up, Here's 3 You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/24/2021
|
JAGX Stock Price: 6.4% Increase Explanation
- The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by 6.4% on Friday, May 21. This is why it happened.
- 05/24/2021
|
Best Penny Stocks To Buy Right Now? 3 To Know Before Next Week
- After this week's market pullback, some of these penny stocks are trending into the weekend. The post Best Penny Stocks To Buy Right Now?
- 05/21/2021
|
Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting
- SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea ("CRD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned subsidiary, and Napo's collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be held virtually from June 4-8, 2021. In addition, two CRD-related abstracts from Napo and its collaborators have been accepted for online publication at ASCO.
- 05/20/2021
|
Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community
- Newly created Jaguar Health Community Instagram page introduces jaguar-themed contest SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company recently launched a new social media channel for stakeholders and the Company's growing community of followers. The ‘Jaguar Health Community' Instagram page will serve as a central social media communications hub for all community-building and educational awareness activities.
- 05/19/2021
|
Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs
- Canalevia would be first and only FDA-approved plant-based medicine for dogs that suffer from diarrhea during chemotherapy Canalevia will be available by fourth quarter 2021, if conditionally approved SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided updates regarding the development program for the Company's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea (CID) in dogs and exercise-induced diarrhea (EID) in dogs. There currently is no FDA-approved anti-secretory prescription product to manage these types of debilitating diarrhea in dogs.
- 05/18/2021
|
Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q1 2021 Results - Earnings Call Transcript
- Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q1 2021 Results - Earnings Call Transcript
- 05/17/2021
|
Recap: Jaguar Health Q1 Earnings
- Shares of Jaguar Health (NASDAQ:JAGX) decreased 1.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 83.93% year over year to ($0.09), which missed the estimate of ($0.02).
- 05/17/2021
|
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective May 12, 2021, the Company granted nonstatutory stock options for the purchase of up to 4,000 shares of the Company's common stock to New Employee 1, nonstatutory stock options for the purchase of up to 4,750 shares of the Company's common stock to New Employee 2, and nonstatutory stock options for the purchase of up to 40,000 shares of the Company's common stock to New Employee 3, as inducement awards under the Company's Inducement Award Plan. These nonstatutory stock options granted to the three new employees referenced above have an exercise price of $1.22 per share, representing the closing price of Jaguar's common stock as reported by Nasdaq on the grant date.
- 05/14/2021
|
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, June 11, 2021 and Encourages All Shareholders to Vote
- Based on a preliminary review of votes cast, over 80% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene June 11, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum Reminder: Jaguar to host investor webcast Monday, May 17th at 8:30 AM Eastern Time regarding Q1 2021 financials & business updates SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that its Annual Meeting of Stockholders held on May 13, 2021 (the "Annual Meeting") was adjourned due to a lack of quorum. The adjourned meeting will be held at 8:30 a.m.
- 05/14/2021
|
Jaguar Health to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates
- Webcast registration link appears below Company plans to file Q1 2021 10-Q on May 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a webcast on Monday, May 17, 2021 at 8:30 a.m. Eastern Time to review first-quarter 2021 financials and provide business updates.
- 05/11/2021
|
7 Reddit Penny Stocks With Interesting Plans
- So, which Reddit penny stocks with ambitious plans could pay off down the road? Consider these seven high-risk, high-potential plays as ones where risk/return leans in your favor: The post 7 Reddit Penny Stocks With Interesting Plans appeared first on InvestorPlace.
- 05/07/2021
|
Jaguar Health Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan
- Company terminates at-the-market (ATM) financing program SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement (the "Transaction") with North American institutional investors for the purchase and sale of 7,647,000 shares of common stock for gross proceeds of approximately $10.8 million in a registered direct offering. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in connection with the Transaction.
- 04/29/2021
|
Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract Regarding Patient Outcomes Associated with Cancer Therapy-Related Diarrhea Accepted for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting
- SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea ("CTD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned subsidiary, and Napo's collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be held virtually from June 4-8, 2021. The title of the accepted poster presentation is: The impact of cancer-related diarrhea on changes in cancer therapy patterns: Real world evidence Poster Session: Symptoms and Survivorship The lead author of the study is Pablo C.
- 04/29/2021
|
Best Penny Stocks to Buy? You Might Want to Add These 3 To Your Watchlist
- Creating a penny stock watchlist? You should check these 3 out The post Best Penny Stocks to Buy?
- 04/23/2021
|
REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., Jaguar's New Italian Subsidiary
- Registration link for webcast interview appears below SAN FRANCISCO, CA / ACCESSWIRE / April 21, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today about the Innovators with Jane King interview of Lisa Conte, the Company's founder, president, and CEO, and Josh Mailman, the lead sponsor of the Dragon special purpose acquisition company (the "Dragon SPAC"), that will air during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern to provide a business overview of Napo EU S.p.A. ("Napo EU"), Jaguar's wholly owned Italian subsidiary.
- 04/21/2021
|
Jaguar Health Announces Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., the Company's New Italian Subsidiary
- Registration link for webcast interview appears below Company premiers Napo EU's new logo and branding, now live on Napoeu.com website SAN FRANCISCO, CA / ACCESSWIRE / April 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that an Innovators with Jane King interview of Lisa Conte, the Company's founder, president, and CEO, will be aired during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern to provide a business overview of Napo EU S.p.A. ("Napo EU"), Jaguar's wholly owned Italian subsidiary.
- 04/19/2021
|
7 Reddit Penny Stocks to Buy for a Biotech Boom
- So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.
- 04/16/2021
|
Jaguar Health and Napo Pharmaceuticals Announce Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting
- SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with cancer therapy-related diarrhea ("CTD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned subsidiary, and Napo's collaborators has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be held virtually from June 4-8, 2021. Two other CTD-related abstracts from Napo and its collaborators have also been accepted for online publication for the 2021 ASCO Annual Meeting.
- 04/14/2021
|
Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC
- Stock purchase price under the agreement increases to $3.00 per share SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar has entered into an amendment (the "Amendment") to the March 24, 2020 equity purchase agreement (the "Equity Purchase Agreement") with Oasis Capital, LLC ("Oasis Capital"). As previously announced, Oasis is committed to purchasing up to an aggregate of $2.0 million of Jaguar common stock over the 36-month term of the Equity Purchase Agreement.
- 04/08/2021
|
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective March 26, 2021, the Company granted nonstatutory stock options for the purchase of up to 2,000 shares of the Company's common stock to new employee 1, nonstatutory stock options for the purchase of up to 3,000 shares of the Company's common stock to new employee 2, nonstatutory stock options for the purchase of up to 4,000 shares of the Company's common stock to new employee 3, nonstatutory stock options for the purchase of up to 5,000 shares of the Company's common stock to new employee 4, and nonstatutory stock options for the purchase of up to 35,000 shares of the Company's common stock to new employee 5, as inducement awards under the Company's Inducement Award Plan. These nonstatutory stock options granted to the five new employees referenced above have an exercise price of $1.84 per share, representing the closing price of Jaguar's common stock as reported by Nasdaq on the grant date.
- 04/02/2021
|
Jaguar Health Has Enough Short-Term Catalysts To Make It Interesting
- It's easy to dismiss JAGX stock as just another beneficiary of the equity bull market. However, Jaguar Health has made significant strides during the last year.
- 04/02/2021
|
JAGX Stock: 15 Things Giving Jaguar Health Shares a Jolt Today
- Jaguar Health (JAGX) stock is heading higher on Thursday following the release of the biopharma company's earnings for the full year of 2020. The post JAGX Stock: 15 Things Giving Jaguar Health Shares a Jolt Today appeared first on InvestorPlace.
- 04/01/2021
|
JAGX Stock Price Increased Over 10% Pre-Market: Why It Happened
- The stock price of Jaguar Health, Inc. (NASDAQ:JAGX) increased by over 10% pre-market. This is why it happened.
- 04/01/2021
|
Jaguar Health Reports 2020 Financial Results and Business Updates
- Mytesi® net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2020. 2020 Company Financial Results: Mytesi® Net Product Revenue: 2020 Mytesi net sales were approximately $9.3 million, and Mytesi gross (non-GAAP) sales were approximately $20.4 million, an increase of 64% and 148%, respectively, year over year.
- 03/31/2021
|
Jaguar Health Announces Selection of Investment Bank and Nominated Advisor for Proposed Merger of the Dragon SPAC and Napo EU, Jaguar's Italian Subsidiary
- Update regarding March 15, 2021 meeting with European regulatory authority regarding potential Covid-related indication for crofelemer SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company supports the selection of the investment bank and nominated advisor ("NOMAD") made by the lead sponsor of the planned Dragon special purpose acquisition company (the "Dragon SPAC"). The Dragon SPAC anticipates listing on AIM Italia and merging with its named target, Napo EU S.p.A.
- 03/30/2021
|
Jaguar Health Announces Winner of International Day of Forests Contest
- New educational contest to begin in April in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV SAN FRANCISCO, CA / ACCESSWIRE / March 22, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that Maribel P.L., a nurse from New York, is the winner of the Company's International Day of Forests educational awareness contest.
- 03/22/2021
|
Jaguar Health Announces Incorporation of Napo EU Subsidiary in Italy
- Napo EU will serve as the foundation of the Company's efforts to address the growing burden - particularly in Europe - of the inflammatory diarrhea associated with long-hauler syndrome in the post COVID-19 patient population In honor of International Day of Forests, Company is conducting a survey contest to raffle off a signed print of an original painting of a Jaguar by Anthony J. Conte - link to entry form appears below SAN FRANCISCO, CA / ACCESSWIRE / March 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that Napo EU S.p.A.
- 03/15/2021
|
8 Biotech Penny Stocks for Investors to Watch
- Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.
- 03/10/2021
|
Jaguar Health Signs Definitive Agreement for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream
- No royalty payments due for 36 months Company has started to identify key opinion leader physicians in the US as well as Europe focused on addressing the symptoms - including gastrointestinal distress - that afflict a significant proportion of COVID-19 survivors for an extended period after recovery SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has signed the definitive agreement (the "Agreement") related to the previously announced term sheet for a third non-dilutive royalty financing transaction, pursuant to which Jaguar is selling to the lender for an aggregate purchase price of $5 million (the "Royalty Purchase Price") a royalty interest in future potential crofelemer (Mytesi®) sales for the proposed COVID-related indication in long-hauler patients (as defined below), for which the Company is currently exploring the pathway of conditional marketing authorization in the European Union. The COVID-related indication is the initial indication to be pursued by Napo EU, the exclusive target of the planned Dragon special purpose acquisition company (the "Dragon SPAC"), which is anticipated to be listed on AIM Italia.
- 03/09/2021
|
Why Are Jaguar Health Shares Surging Today?
- Continuing Friday's rally, Jaguar Health Inc (NASDAQ: JAGX) stock has surged on Monday as the investors react to the news of its third royalty financing agreement announced on Friday. The company entered a binding term sheet for $5 million a royalty interest in future potential crofelemer (Mytesi) sales for the proposed COVID-related indication in long-hauler patients.
- 03/08/2021
|
JAGX Stock Price Increased Over 55% Intraday: Why It Happened
- The stock price of Jaguar Health Inc (NASDAQ: JAGX) has increased by over 55% during intraday trading. This is why it happened.
- 03/08/2021
|
JAGX Stock: Why Popular Jaguar Health Is Climbing Today
- JAGX stock is on the move today after Jaguar Health announced a plan to secure $5 million of funding. Here's what to know now.
- 03/08/2021
|
7 Meme Stocks That Have Retail Traders ‘Stonk-ing' Up
- These seven meme stocks have been caught up in the short squeeze, and have grown immensely despite showing little promise from their fundamentals. The post 7 Meme Stocks That Have Retail Traders ‘Stonk-ing' Up appeared first on InvestorPlace.
- 03/08/2021
|
Is the Parabolic Rise of JAGX Stock Too Good to Be True?
- JAGX stock has risen dramatically on positive sentiment about the potential for an expanded market for the company's core Mytesi drug. The post Is the Parabolic Rise of JAGX Stock Too Good to Be True?
- 03/05/2021
|
Jaguar Health Enters Binding Term Sheet for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream
- No royalty payments due for 36 months Planned COVID-related indication in long-hauler patients is the lead focus for crofelemer at Napo EU, the exclusive target of the planned Dragon SPAC, which is pursuing listing on AIM Italia Company expects to provide additional updates regarding Napo EU next week SAN FRANCISCO, CA / ACCESSWIRE / March 5, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has entered a binding agreement of terms (the "Term Sheet") for a third non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the lender for an aggregate purchase price of $5 million (the "Royalty Purchase Price") a royalty interest in future potential crofelemer (Mytesi®) sales for the proposed COVID-related indication in long-hauler patients (as defined below), for which the Company is currently exploring the pathway of conditional marketing authorization in the European Union. Jaguar intends to use the proceeds from the proposed transaction to support regulatory activities associated with the Company's development pipeline, including supporting the development program for crofelemer for the prophylaxis and/or symptomatic relief of inflammatory diarrhea, initially to be studied in a long-hauler COVID-19 recovery patient population (the "COVID-related indication").
- 03/05/2021
|
Jaguar Health Is on a Noble Mission But the Stock Needs a Nudge
- Jaguar Health is doing the right thing while JAGX stock is on the skids. It is falling into support, so there could be relief coming.
- 03/03/2021
|
Is Jaguar Health Ready to Bounce Back From a Lousy February?
- Jaguar Health did not have a good February. Down 25% through Feb. 25, it might be time to give up on JAGX stock despite SPAC spinoff.
- 03/01/2021
|
7 Biotech Stocks Focused on Chronic Covid Treatment
- Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.
- 02/22/2021
|
Jaguar Health Has Promise, But It's Not a Good Investment Yet
- JAGX stock needs to prove the effectiveness of its drug candidates before investors can consider jumping on its bandwagon. The post Jaguar Health Has Promise, But It's Not a Good Investment Yet appeared first on InvestorPlace.
- 02/18/2021
|
Jaguar Health In MoU With Dragon SPAC As Its Subsidiary Seeks Approval For Crofelemer In Europe
- Jaguar Health Inc (NASDAQ: JAGX) has signed a Memorandum of Understanding (MoU) with the lead sponsor of the planned Dragon special purpose acquisition company, pursuing a listing on AIM Italia. Per the MOU, Napo EU, the company's anticipated subsidiary in Italy, will be the named target of the Dragon SPAC and has granted latter exclusivity to list on AIM Italia and negotiate and finalize documentation for the contemplated merger transaction.
- 02/18/2021
|
JAGX Stock: What to Know as SPAC News Sends Jaguar Health Soaring
- JAGX stock is on the move today after the popular company announced it had signed a memorandum of understanding for a SPAC deal. The post JAGX Stock: What to Know as SPAC News Sends Jaguar Health Soaring appeared first on InvestorPlace.
- 02/18/2021
|
Hold Jaguar Health Stock for SPAC Spin-Off and Covid-19 Connection
- JAGX stock holders must weigh the impact of an intriguing European SPAC and a potential treatment option for Covid-19 long-haul patients. The post Hold Jaguar Health Stock for SPAC Spin-Off and Covid-19 Connection appeared first on InvestorPlace.
- 02/16/2021
|
9 Meme Stocks That Social Media Won't Shut Up About
- It may be fun to dabble in meme stocks. But, don't consider it a surefire path to investing profits.
- 02/12/2021
|
Jaguar Health Has a Strong Outline, But the Story Is Unclear
- The 12-month, 300% gain with JAGX stock has a lot of headline news. There's a lot to like, but will Jaguar be able to build on its gains?
- 02/12/2021
|
Jaguar Health Isn't a Healthy Investment, but It Could Be a Profitable One
- Likely, no one would suggest that JAGX stock is a fundamentally sound investment. But the current market environment makes shares a compelling short-term trade.
- 02/09/2021
|
Jaguar Health Stock Remains a Speculative Investment At Best
- Jaguar Health stock is a speculative investment at best. JAGX stock is hard to nail down as it's hard to understand its numerous and strange financings.
- 02/03/2021
|
Do We Know Enough About Napo Pharma's SPAC To Invest In Jaguar Health?
- Jaguar Health might merge part of its Napo Pharmaceuticals unit with a SPAC. What's this mean for JAGX stock over the long haul?
- 02/01/2021
|
Robinhood Stock Ban Expanded: What 50 Stocks Are on Restricted List?
- Robinhood bans now include trading restrictions on 50 popular Reddit stocks like SNDL, CCIV, GME, AMC and NOK. Here's what to know.
- 01/29/2021
|
JAGX Stock: Jaguar Health's Napo EU to Go Public Via SPAC
- JAGX stock may be slumping today, but new SPAC merger news could turn things around. Here is what you should know about the Napo EU deal now.
- 01/27/2021
|
Proposed SPAC Merger Makes Jaguar Health Stock Intriguing
- If you've been sitting on the sidelines when it comes to JAGX stock, an important meeting should give you the excuse you've been waiting for. The post Proposed SPAC Merger Makes Jaguar Health Stock Intriguing appeared first on InvestorPlace.
- 01/26/2021
|
What You Need to Know About Jaguar Health Stock
- Jaguar Health is showing better vital signs lately. However, there are still some things to consider before pouncing on JAGX stock.
- 01/22/2021
|
JAGX Stock Surges Ahead of Jaguar Health SPAC Merger Meeting
- Jaguar Health (JAGX) stock is on the rise Thursday after announcing a meeting concerning an upcoming SPAC merger in Italy. The post JAGX Stock Surges Ahead of Jaguar Health SPAC Merger Meeting appeared first on InvestorPlace.
- 01/21/2021
|
JAGX Stock Price Increases Over 15% Pre-Market: Why It Happened
- The stock price of Jaguar Health Inc (NASDAQ: JAGX) has increased by over 15% pre-market today. This is why it happened.
- 01/21/2021
|
4 Hot NASDAQ Stocks: Ideanomics (NASDAQ: IDEX), Jaguar Health (NASDAQ: JAGX), Marathon Patent Group (NASDAQ: MARA), and Riot Blockchain (NASDAQ: RIOT)
- If the first week of 2021 is the sign of things to come this year, traders and investors are going to make a lot of money. 4 NASDAQ stocks that really lit up the first week of 2021 were Ideanomics (NASDAQ: IDEX), Jaguar Health (NASDAQ: JAGX), Marathon Patent Group (NASDAQ: MARA), and Riot Blockchain (NASDAQ: […]
- 01/19/2021
|
Jaguar Health Provides Replay Link & High-level Overview of January 14th Investor Webcast
- SAN FRANCISCO, CA / ACCESSWIRE / January 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided the replay link for the Company's January 14, 2021 investor webcast and a recap of the key points from the presentation. To access the audio recording and slides from the webcast, click here.
- 01/15/2021
|
Why Regeneron, Jaguar Health And Seneca Are Moving Today
- Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million doses of its COVID-19 antibody cocktail bringing the total number to over 1.5 million doses. Regeneron discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.
- 01/13/2021
|
Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher
- This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.
- 01/13/2021
|
Don't Try to Tame Jaguar Health Stock As It Rips Higher
- If you believe in the future of plant-based medical treatments, then a long position in JAGX stock could offer exposure to this technology. The post Don't Try to Tame Jaguar Health Stock As It Rips Higher appeared first on InvestorPlace.
- 01/12/2021
|
Jaguar Health to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference the Week of January 11th and at 4:30 pm Eastern on Tuesday, January 19th at the NobleCon17 Virtual Conference
- REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.
- 01/12/2021
|
Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler' COVID-19 Recovery Patients in Europe
- New COVID-19 strain estimated to have tripled number of infections in England during November 2020 lockdown Investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.
- 01/11/2021
|
Why Jaguar Health Stock Skyrocketed 49% Today
- The developer of plant-based medicines has a promising drug pipeline.
- 01/08/2021
|
JAGX Stock: 11 Things to Know as Jaguar Health Rockets Higher
- JAGX stock is on the move today as Jaguar Health continues to gain attention. Here's what you should know about the biopharma play now.
- 01/08/2021
|
JAGX Stock Price Increased Over 20%: Why It Happened
- The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased over 20% shortly after the market opened this morning. This is why it happened.
- 01/08/2021
|
Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
- Lechlemer development focused on possible tropical disease priority review voucher SAN FRANCISCO, CA / ACCESSWIRE / January 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the 28-day preclinical toxicology and safety study in dogs began today, January 6, 2021, to support development of lechlemer, the second generation, plant-based anti-secretory drug candidate of Napo Pharmaceuticals ("Napo"), Jaguar's wholly owned subsidiary, for the symptomatic relief of diarrhea from cholera. As previously announced, Napo is receiving preclinical services from the National Institute of Allergy and Infectious Diseases ("NIAID") to support lechlemer development.
- 01/06/2021
|
Jaguar Health shares soar 40% in heavy volume, on track for 18-month high
- Shares of Jaguar Health Inc., a developer of plant-based medicines for people and animals, soared more than 40% on Tuesday in heavy volume, extending their recent strong gains and putting the stock on track for its highest level since mid-2019.
- 01/05/2021
|
JAGX Stock: 12 Things to Know About Fast-Moving Jaguar Health
- JAGX shares are once again on the move this week. Here's what you should know about the maker of the antidiarrheal treatment Mytesi.
- 01/05/2021
|
JAGX Stock: Why Jaguar Health Shares Are Surging 150% Today
- JAGX stock is up on news that Jaguar Health just signed a royalty deal that will allow the company to pursue new FDA approvals. The post JAGX Stock: Why Jaguar Health Shares Are Surging 150% Today appeared first on InvestorPlace.
- 12/23/2020
|
Why Cellectar, Jaguar Health And More Are Moving Today
- Cellectar Biosciences (NASDAQ: CLRB) shares are trading lower on Wednesday after the company priced a $24.5 million offering at $1.35 per share. Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company.
- 12/23/2020
|
Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream
- No royalty payments due for 18-24 months Proceeds will be allocated to support regulatory activities associated with the Company's development pipeline, including funding the recently initiated pivotal clinical trial for crofelemer (Mytesi®) for cancer therapy-related diarrhea (CTD), for which patient enrollment is progressing SAN FRANCISCO, CA / ACCESSWIRE / December 23, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has signed an agreement (the "Agreement") with a secured lender (the "Lender") for a non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the Lender for an aggregate purchase price of $6 million (the "Royalty Purchase Price") a royalty interest entitling the Lender to receive 2.0x the Royalty Purchase Price of future royalties of Mytesi® (crofelemer) and lechlemer and certain up-front license fees and milestone payments from licensees and/or distributors as well as any interest, fees, and charges in accordance with the terms set forth in the Agreement (the "Royalty Repayment Amount"), and to pay interest on the Royalty Repayment Amount at the rate of ten percent per annum until the same is paid in full. Jaguar intends to use the proceeds to support regulatory activities associated with the Company's development pipeline, including funding continued patient enrollment for the pivotal Phase 3 trial of crofelemer (Mytesi) for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy ("cancer therapy‑related diarrhea" (CTD)), which the Company's wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), initiated this past October.
- 12/23/2020
|
JAGX Stock Price Increases Over 50%: Why It Happened
- The stock price of Jaguar Health, Inc. (NASDAQ:JAGX) is trading at more than 50% today. This is why it happened.
- 12/01/2020
|
Jaguar Health: 10 Things for JAGX Stock Investors to Know About the Pharmaceutical Company
- Jaguar Health (JAGX) is on the move Tuesday as shares of JAGX stock continue to rise and InvestorPlace has what investors need to know. The post Jaguar Health: 10 Things for JAGX Stock Investors to Know About the Pharmaceutical Company appeared first on InvestorPlace.
- 12/01/2020
|
Why Jaguar Health And OncoCyte Are Trading Higher Today
- Jaguar Health (NASDAQ: JAGX) shares are trading higher on Monday after the company announced its plans to develop and commercialize its Crofelemer. Jaguar Health is a commercial-stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products.
- 11/30/2020
|
Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q3 2020 Results - Earnings Call Transcript
- Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q3 2020 Results - Earnings Call Transcript
- 11/16/2020
|
Jaguar Health Provides Updates on Investigator-Initiated Trials of Crofelemer (Mytesi)
- Company shares updates on investigator-initiated trials of crofelemer (Mytesi®), a novel FDA-approved plant-based oral prescription medicineSAN FRANCISCO, CA / ACCESSWIRE / August 19, 2020 / Jaguar Health, Inc.
- 08/19/2020
|
Jaguar Health Submits Final Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs
- Canalevia would be first and only FDA-approved plant-based medicine for the more than 50,000 dogs that suffer from diarrhea during chemotherapySAN FRANCISCO, CA / ACCESSWIRE / August 18, 2020 / Jaguar Health, Inc.
- 08/18/2020
|
Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into a Second Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020
- SAN FRANCISCO, CA / ACCESSWIRE / August 14, 2020 / Jaguar Health, Inc.
- 08/14/2020
|
Jaguar Health, Inc. Reports 2020 Second Quarter Financial Results
- Q2 2020 Mytesi net sales and gross sales were approximately $3.
- 08/13/2020
|
Jaguar Health to Host Investor Call August 13th at 8:30 a.m. Eastern Regarding Q2 2020 Financials and Business Updates
- Company Plans to File Q2 2020 10-Q on August 13, 2020Save the Date: Company to host virtual disease awareness event on October 20, 2020 focused on cancer therapy-related diarrheaSAN FRANCISCO, CA / ACCESSWIRE / August 11, 2020 / Jaguar Health, Inc.
- 08/11/2020
|
Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy‑Related Diarrhea | | IT Business Net
- A significant proportion of patients undergoing cancer therapy experience diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "
- 08/06/2020
|
Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy‑Related Diarrhea A significant proportion of patients undergoing cancer therapy experience diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced today the activation of the investigational new drug (IND) application filed by the | MarketScreener
|
Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy‑Related Diarrhea
- A significant proportion of patients undergoing cancer therapy experience diarrheaSAN FRANCISCO, CA / ACCESSWIRE / August 6, 2020 / Jaguar Health, Inc.
- 08/06/2020
|
5 Value Stocks In The Healthcare Sector
- What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.The following stocks are considered to be notable value stocks in the healthcare sector: 1. Genesis Healthcare (NYSE: GEN) - P/E: 1.79 2. Vanda Pharmaceuticals (NASDAQ: VNDA) - P/E: 4.73 3. XBiotech (NASDAQ: XBIT) - P/E: 1.0 4. Salarius Pharmaceuticals (NASDAQ: SLRX) - P/E: 1.74 5. Jaguar Health (NASDAQ: JAGX) - P/E: 0.09Genesis Healthcare's earnings per share for Q1 sits at 0.28, whereas in Q4, they were at -0.1. Genesis Healthcare does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, Vanda Pharmaceuticals experienced a decrease in earnings per share, which was 0.08 in Q4 and is now 0.01. Vanda Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.XBiotech has reported Q4 earnings per share at -0.63, which has decreased by 320.0% compared to Q3, which was -0.15. XBiotech does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Salarius Pharmaceuticals has reported Q1 earnings per share at -0.22, which has increased by 50.0% compared to Q4, which was -0.44. Salarius Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Jaguar Health saw an increase in earnings per share from -1.62 in Q4 to -0.56 now. Jaguar Health does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * 5 Value Stocks In The Real Estate Sector * Unusual Options Activity Insight: Facebook * Unusual Options Activity Insight: Target(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/03/2020
|
5 Value Stocks In The Healthcare Sector
- What Defines a Value Stock?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E...
- 08/03/2020
|
Jaguar’s F-Type update falls short
- The 2021 F-Type R-Dynamic just isn’t what the brand requires to stay competitive
By HANNAH ELLIOTT WHEN it debuted in 2015, the Jaguar F-Type was a “Very Exciting Car”. It was the first cool coupe Jaguar had made since the XK of 2006. It drove with a focused ease that channelled sports cars worth […]
- 07/27/2020
|
Tesla’s Brand Believers
- Tesla scored poorly on the recent 2020 J.D. Power Initial Quality Survey. On the other hand, Tesla ranked highest on J.D Power’s 2020 APEAL Strong brand image can overcome negative quality issues
- 07/27/2020
|
Driving may never be the same after coronavirus. But what a ride it’s been!
- Lifestyle changes after lockdown could mean the end of our reliance on cars. Some of us will miss the age of the automobile
- 07/26/2020
|
Bespoke Aston Martin Vanquish 25 is a retro supercar dream - CityAM
- Car design guru Ian Callum has given the Aston Martin Vanquish a modern makeover, with sharper handling, plenty of carbon and Apple CarPlay
- 07/25/2020
|
La exquisitez del Jaguard XJ 2021 es aún una incógnita
- Los automóviles de lujo que fabrica la firma inglesa Jaguar no dejan indiferentes a nadie. La nueva berlina Jarguar XJ 2021 será emocionantemente bella, confortable y potente.
- 07/24/2020
|
Jaguar creates contactless screen that knows where you'd press before you do it
- JAGUAR has developed a “contactless” touchscreen that keeps drivers’ eyes on the road – and could even reduce the spread of bad bugs. The so-called “predictive touch” …
- 07/22/2020
|
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SAN FRANCISCO, CA / ACCESSWIRE / July 22, 2020 / Jaguar Health, Inc.
- 07/22/2020
|
Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated July 21, 2020 for Lechlemer Plant-based Drug Candidate for Cholera | | IT Business Net
- SAN FRANCISCO, CA / ACCESSWIRE / July 22, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the 28-day preclinical toxicology and safety stu
- 07/22/2020
|
India’s nuclear strategy shifts focus from Pakistan to China, Beijing now in range of New Delhi's missiles: Report
- The report said that this posture has likely been reinforced after the 2017 Doklam standoff, during which Chinese and Indian troops were placed on high alert over a dispute near the Bhutanese border.
- 07/22/2020
|
Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated July 21, 2020 for Lechlemer Plant-based Drug Candidate for Cholera
- SAN FRANCISCO, CA / ACCESSWIRE / July 22, 2020 / Jaguar Health, Inc.
- 07/22/2020
|
Most Owners Satisfied with New Vehicles; Some Truly Love Them Despite Their Flaws, J.D. Power Finds
- When it comes to driving sales, as well as generating brand loyalty and advocacy, vehicles that create joy for their owners often overcomes any negati
- 07/22/2020
|
Jaguar Health Reports Voting Results from July 21, 2020 Special Meeting of Stockholders | | IT Business Net
- All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / July 21, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the vo
- 07/21/2020
|
Jaguar Health Reports Voting Results from July 21, 2020 Special Meeting of Stockholders
- All Proposals ApprovedSAN FRANCISCO, CA / ACCESSWIRE / July 21, 2020 / Jaguar Health, Inc.
- 07/21/2020
|
Massive clean engine manufacturing milestone for Jaguar Land Rover
- The future is electric for Jaguar Land Rover and its Engine Manufacturing Centre where a full line-up of Ingenium powertrain technologies now celebrates a 1.5-million unit milestone.
- 07/20/2020
|
FDA Invites Jaguar Health to Expedite Submission of Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs
- Canalevia would be first and only FDA-approved plant-based medicine for the more than 50,000 dogs that suffer from diarrhea during chemotherapySAN FRANCISCO, CA / ACCESSWIRE / July 20, 2020 / Jaguar Health, Inc.
- 07/20/2020
|
July 20, 1980, Forty Years Ago: Indira On The Bomb
- Prime Minister Indira Gandhi asked: Would possession of one or two bombs be a deterrent to conflict?
- 07/19/2020
|
Steve Coogan’s ‘perfect’ Jaguar E-Type up for sale - CityAM
- A rare Jaguar E-Type owned by comedy actor Steve Coogan is coming up for auction. Aha! Find out all the details right here.
- 07/19/2020
|
Ex-Economic Hit Man John Perkins Believes We Have Reached A Tipping Point
- Not everyone has the background or capacity to start a company like Carbon Engineering, GlassPoint Solar, or Heliogen, but that doesn’t mean everyone is off the hook. Ex-Economic Hit Man, John Perkins, wants you to change the world by changing your perceptions.
- 07/17/2020
|
BMW Claims iX3 Beats e-tron On Range, But What's The Price & Availability?
- Early this morning in Munich, BMW Chairman Oliver Zipse presented an update on the BMW iX3 full electric SUV due out later this year.
- 07/14/2020
|
Britain's Bird to join Jaguar Formula E team
- Britain's Sam Bird, the only driver to have won a Formula E race in every year of the all-electric series, is joining the Jaguar team for season seven that is due to start in Chile next January.
- 07/14/2020
|
Motor racing: Britain's Bird to join Jaguar Formula E team
- Britain's Sam Bird, the only driver to have won a Formula E race in every year of the all-electric series, is joining the Jaguar team for season seven that is due to start in Chile next January.
- 07/14/2020
|
BMW's electric iX3 to duel it out with Tesla Model X and Jaguar I-Pace
- Not only is the German car giant's new iX3 its first pure electric SUV, it's also the first to use sounds from the creator of such Hollywood blockbusters as Gladiator, Batman, Pirates of the Caribbean.
- 07/14/2020
|
Motor racing: Britain's Bird to join Jaguar Formula E team
- Britain's Sam Bird, the only driver to have won a Formula E race in every year of the all-electric series, is joining the Jaguar team for season seven that is due to start in Chile next January.
- 07/14/2020
|
Motor racing-Britain's Bird to join Jaguar Formula E team | International
- Britain's Sam Bird, the only driver to have won a Formula E race in every year of the all-electric series, is joining the Jaguar team for season seven that is due to start in Chile next January.
Season seven is due to start in Santiago on January 16.
- 07/14/2020
|
Analyst Corner: ‘Buy’ rating on Tata Motors with target price of Rs 126
- Post the resumption of operations, the Range Rover Sport, the new Range Rover Evoque, and the Land Rover Discovery Sport emerged as the bestselling vehicles.
- 07/14/2020
|
Motor racing: Britain's Bird to join Jaguar Formula E team
- Motor racing: Britain's Bird to join Jaguar Formula E team
- 07/14/2020
|
JLR hit by huge delay at Castle Bromwich plant in wake of coronavirus
- The Midlands car giant, with factories in Solihull, Castle Bromwich and Wolverhampton, will announce the delay in the wake of the coronavirus crisis
- 07/13/2020
|
Jaguar Land Rover reported to be delaying launch of electric XJ model
- The Jaguar XJ is one of a number of models set to be produced at a transformed Castle Bromwich plant
- 07/12/2020
|
Two pristine rare Jaguar E-Types to go under the hammer
- The Fixed Head Coupe and a Roadster were both produced at Browns Lane in Coventry in 1961
- 07/12/2020
|
Electronia Brings Energica Electric Super Bikes To South Africa, Targets More Countries Across The Continent
- Vanderbijlpark-based Electronia is selling Energica electric superbikes in South Africa. The Modena- (Italy) based Energica is also the sole manufacturer in the Moto E Championship. Electronia is bringing the 21.5 kWh Energica EGO+, EVA RIBELLE, and the EVA ESSEESSE9+ models to South Africa initially, but plans to open up sales in other African countries soon.
- 07/12/2020
|
Joe Biden's niece Caroline, 33, was 'arrested last year for DUI'
- Caroline Biden, the 33-year-old daughter of the former vice president's younger brother, James Biden Sr, was taken into custody last year in Lower Merion Township, Pennsylvania.
- 07/11/2020
|
Electric cars: five best buys, from new models to used bargains
- Most new vehicles can now exceed 200 miles on a single charge. We look at options for every budget
- 07/11/2020
|
JLR round-up: DHL job cuts, Jaguar's future and the new boss
- A selection of news on Britain's biggest car maker
- 07/11/2020
|
Jaguar’s future - what’s next for the Big Cat?
- Speculation abounds as to what Jaguar Land Rover might do going forward
- 07/10/2020
|
Charges Filed Against Man Accused Of Hitting Protesters On I-5
- Prosecutors say Dawit Kelete sped onto the closed freeway and hit two protesters, killing one, early Saturday morning.
- 07/08/2020
|
Rimac C_Two Electric Hypercar to Reach Customers by 2021
- The US$2.2 million two-seater can reach 60 mph in less than two seconds
- 07/08/2020
|
Could Jaguar launch a hatchback as a saloon replacement?
- It could take its styling cues from the stunning R-D6 - a concept dating back to 2003
- 07/08/2020
|
Boy, 13, fighting for life after hit and run as boy, 15, arrested
- A 15-year-old boy has been since arrested on suspicion of causing serious injury by dangerous driving.
- 07/08/2020
|
Boy, 13, fighting for life after hit-and-run Jaguar crash as teen, 15, held
- A 13-YEAR-old boy is fighting for his life in hospital after being hit by a Jaguar allegedly driven by a 15-year-old. Cops were called to reports of a hit and run between a car and a teen at…
- 07/08/2020
|
Boy, 15, arrested after 13-year-old injured in 'hit and run with Jaguar'
- A teenage boy is fighting for his life in hospital after allegedly being struck by a Jaguar which mounted the pavement in Makerfield, Wigan at around 4.30pm yesterday
- 07/08/2020
|
Boy, 13, fights for life following hit-and-run - a 15-year-old has been arrested
- A 15-year-old boy has been arrested on suspicion of causing serious injury by dangerous driving
- 07/08/2020
|
Boy, 13, fighting for his life and teen arrested after Jaguar 'hit-and-run'
- Greater Manchester Police say the teen is in a life-threatening condition after a Jaguar car mounted a pavement in Ashton, Makefield, and struck him down
- 07/08/2020
|
Boy, 13, fighting for his life after hit-and-run
- A 15-year-old boy has since been arrested on causing serious injury by dangerous driving
- 07/08/2020
|
Taxis under pressure to switch to electric
- Programme for Government says taxis have ‘disproportionate impact’ on air quality
- 07/08/2020
|
Jaguar Land Rover To Launch Subscriptions | PYMNTS.com
- Jaguar Land Rover is launching a new subscription service, called Pivotal, which is debuting in the U.K. after completion of a trial program.
- 07/07/2020
|
Jaguar’s F-Type Needs a Big Refresh. The 2021 Update Falls Short - BNN Bloomberg
- The 2021 F-Type R-Dynamic just isn’t what the brand requires to stay competitive.
- 07/07/2020
|
Pinch me! Jaguar trademark fuels all-electric F-Type successor speculation
- According to a recent trademark filing, Jaguar could name its upcoming electric F-Type succesor the EV-Type. A nod to the E-Type, of course.
- 07/07/2020
|
$1.2 million bail for driver that hit 2 Seattle protesters
- A judge set bail at $1.2 million on Monday for the man accused of driving a Jaguar on to a closed Seattle freeway and hitting two protesters, killing one
- 07/07/2020
|
Jaguar Restaurant Miami Spice To-Go
- Check out the latest community post from one of your neighbors. (The views expressed in this post are the author’s own.)
- 07/06/2020
|
PICTURED: Black man, 27, who knocked down and killed a BLM protester
- Dawit Kelete, main, sped into the crowd in Seattle about 1:40am Saturday, bottom inset, according to police. Summer Taylor, 24, itop nset, succumbed to injuries sustained during the collision.
- 07/06/2020
|
Jaguar Health Subsidiary Napo Pharmaceuticals Completes Filing of Investigational New Drug Application for Crofelemer (Mytesi) for Symptomatic Relief of Cancer Therapy‑Related Diarrhea
- A significant proportion of patients undergoing cancer therapy experience diarrhea SAN FRANCISCO, CA / ACCESSWIRE / July 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") ...
- 07/06/2020
|
Summer Taylor honored for 'standing up for black lives' following death at protest
- Taylor was killed in Seattle on Saturday when a man drove his car into a crowd protesting against police brutality
- 07/06/2020
|
Protester killed on Seattle freeway was dedicated to cause
- A person killed Saturday when a man who drove his car onto a closed Seattle freeway and into a crowd protesting police brutality was being remembered Sunday as someone who was dedicated to the cause
- 07/06/2020
|
Pivotal, la suscripción premium «todo incluido» que te permitirá cambiar de coche cada seis meses
- Se prevé que las suscripciones automovilísticas representen el 10 % de las ventas en Europa y EE. UU. en 2025
- 07/06/2020
|
Pivotal, la suscripción premium «todo incluido» que te permitirá cambiar de coche cada seis meses
- Se prevé que las suscripciones automovilísticas representen el 10 % de las ventas en Europa y EE. UU. en 2025
- 07/06/2020
|
Pivotal, la suscripción premium «todo incluido» que te permitirá cambiar de coche cada seis meses
- Se prevé que las suscripciones automovilísticas representen el 10 % de las ventas en Europa y EE. UU. en 2025
- 07/06/2020
|
One killed as driver barrels into crowd of protesters in Seattle
- One of two people hit by a man who drove his car onto a closed Seattle freeway and into a crowd protesting police brutality has died.
- 07/05/2020
|
Seattle: Auto rast in Black-Lives-Matter-Demo – Frau stirbt - Blick
- Attacke auf Demonstranten in Seattle: Ein Auto ist in eine Gruppe gerast und hat dabei zwei Frauen überfahren. Eine 24-jährige Protestlerin starb dabei.
- 07/05/2020
|
Trump claims victory as US nears 130,000 coronavirus deaths – live
- President claims 99% of US cases are ‘totally harmless’ and insists: ‘We’ve learned how to put out the flame’
- 07/05/2020
|
One of two protesters hit by Seattle wrong-way freeway driver dies in hospital
- A 24-YEAR-old woman died in the hospital just hours after she was one of two protesters hit by a wrong-way driver early Saturday morning. Summer Taylor was killed and Diaz Love, 32, was left in ser…
- 07/05/2020
|
Seattle: one woman killed and one injured as car drives into protesters
- Driver arrested as authorities say I-5 freeway will now be closed to protests
- 07/05/2020
|
Cómo cambiar de coche cada seis meses pagando una sola cuota
- Toda la gama de Jaguar y Land Rover está a su disposición con una nueva fórmula de suscripción mensual a un servicio llamado Pivotal
- 07/05/2020
|
1 of 2 protesters hit by car on closed Seattle highway dies
- Authorities say a car drove onto a closed freeway and into a crowd of protesters, killing one person and critically injuring another
- 07/05/2020
|
New supercar based on Jaguar concept may soon be built by legendary designer Ian Callum
- JAGUAR's former car designer Ian Callum has hinted how a supercar based on the firm's C-X75 concept design is on his list of future projects and could soon hit the road.
- 07/05/2020
|
Car plows into protesters on Seattle highway, injuring two women
- A 27-year-old man is booked on two counts of vehicular assault.
- 07/05/2020
|
PICTURED: Protesters in serious condition after being hit by car
- Diaz Love, 32, and Summer Taylor, 24, remain in serious condition at Seattle's Harborview Hospital after Dawit Kelete, 27, plowed into the pair on a closed off section of Interstate 5.
- 07/05/2020
|
Car driven into Black Lives Matter protesters, seriously injuring two women
- Video captures a white Jaguar driving into a small crowd of demonstrators on a closed highway in Seattle, hitting two women and launching them into the air.
- 07/05/2020
|
Police: 2 women hit by car on Seattle highway amid protest
- Authorities say a 27-year-old man in drove a car onto a closed freeway in Seattle and barreled through a panicked crowd of protesters, critically injuring two women
- 07/04/2020
|
Police: Two women hit by car on Seattle highway amid protests
- A 27-year-old man drove a white Jaguar onto a closed freeway in Seattle early Saturday and barrelled through a panicked crowd of protesters, critically injuring two women, officials said.
- 07/04/2020
|
Justice blocks luxury car from company of wife and son of lawyer who created 3xBit - OBN
- Former headquarters of the 3xBit cryptocurrency exchange, in Campinas (SP) (Photo: Disclosure) The Justice of Paraná determined the blocking of company assets that would be…
- 07/04/2020
|
Government talks, a Hard Top Defender and more - your JLR digest
- A selection of news from far and wide on Britain's biggest car maker
- 07/04/2020
|
2 women hit by car on Seattle highway amid protests: police
- A 27-year-old man drove a white Jaguar onto a closed freeway in Seattle early Saturday and barrelled through a panicked crowd of protesters, critically injuring two women, officials said.
- 07/04/2020
|
2 women hit by car on Seattle highway closed amid protests
- Two women were struck by a white Jaguar whose driver sped through a protest-related closure on a freeway in Seattle. The driver, a 27-year-old man from Seattle, was in custody.
- 07/04/2020
|
Dee Moneey ships and clears first-ever Jaguar smart car into Ghana; video drops
- Dee Moneey, born Desmond Kwame Amoah, has splashed the cash on an car and has left social media users in awe after he cleared a brand new Jaguar smart car.
- 07/04/2020
|
Jaguar Land Rover introduce Pivotal change to enjoying its cars
- Recognising changing customer desires and needs, Jaguar Land Rover has come up with a flexible new financial service that allows more people to experience life behind the wheels of its vehicles. You can also watch a video explaining how the system works here.
- 07/03/2020
|
Prospera Announces Results of Annual and Special Meeting of Shareholders | | IT Business Net
- CALGARY, AB / ACCESSWIRE / July 2, 2020 / Prospera Energy Inc. ("Prospera" or the "Company") (TSXV:PEI)(FRA: OF6A) Prospera shareholders voted in favour of all items of business br
- 07/03/2020
|
Defendants in Stamford fatal jewelry robbery plead not guilty
- The trio off defendants, each from New York, Were arraigned via video at federal court in Bridgeport.
- 07/03/2020
|
Service allows you to get Jaguar or Land Rover without huge deposit
- A new scheme offers an alternative to buying or leasing a car
- 07/02/2020
|
Oldtimer-Vehikel im Wert von 7,7 Milliarden - Blick
- Einen kostbaren Wagenpark bringen die Besitzer von Veteranenfahrzeugen in der Schweiz zusammen. Eine Studie beziffert den Wert jener Autos oder Töffs, die 30 Jahre und älter sind, auf insgesamt 7,7 Milliarden Franken. Ihr Image in der Bevölkerung ist aber weniger gut.
- 07/02/2020
|
In der Schweiz stehen Veteranenfahrzeuge im Wert von 7,7 Milliarden - Schweiz - Liechtensteiner Volksblatt, die Tageszeitung für Liechtenstein
- News, Nachrichten und aktuelle Meldungen aus allen Ressorts. Politik, Wirtschaft, Sport, Leben und Kultur im Überblick.
- 07/02/2020
|
How to Disable Apple CarPlay | Digital Trends
- Apple CarPlay is a great addition to modern cars, but not everyone will find the option attractive. We show you how to disable CarPlay on your vehicle easily.
- 07/02/2020
|
Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
- Working dogs, including search and rescue, military and sled dogs, often suffer diarrhea as a result of engaging in long periods of intense, off-leash exercise. "Elite athletes of all species tend to have more diarrhea than their healthy but more sedentary counterparts, which can interfere with peak physical performance," said Dr. Michael Davis, DVM, Ph.D., DACVIM, DACVSMR, a veterinary physiologist and board-certified specialist in veterinary internal medicine and veterinary sports medicine at Oklahoma State University, where he conducts research on animal exercise physiology and performance.
- 07/02/2020
|
Jaguar Land Rover announces new vehicle subscription service - Evening Express
- Jaguar Land Rover has revealed a new car subscription service, offering drivers a flexible way of running a new car.
- 07/02/2020
|
10 Famous Indian Brands that you thought were International
- Have you ever liked a brand more for its name than its products? Well, we can’t blame you.
- 07/02/2020
|
A first look at the 2021 Polestar 2, Volvo’s all-new EV
- The hatchback has an expected range of 275 miles, and it hits 60 mph in 4.7 seconds.
- 07/02/2020
|
Why these new black bollards have popped up on Coventry roads
- A Coventry firm is behind the design
- 07/02/2020
|
Luxury Connect Business School announces a hybrid program in luxury brand management
- Gurugram (Haryana) [India] July 2 (ANI/NewsVoir): LCBS, India's first and only Luxury Business School has been a pioneer in the luxury management education industry. Launched in 2012 by Abhay Gupta, an industry veteran, the school literally
- 07/02/2020
|
Elon Musk sells four of his Los Angeles mansions
- Elon Musk has sold four of his California homes to mega-mansion developer and designer Ardie Tavangarian.
- 07/01/2020
|
Jaguar Restaurant Introduces "Cava Thursdays"
- Check out the latest community post from one of your neighbors. (The views expressed in this post are the author’s own.)
- 07/01/2020
|
Summer EV deals: huge $15K discounts off Chevy Bolt, Nissan Leaf, Audi, more - Electrek
- With inventory backed up from the pandemic, traditional July 4 EV deals are on steroids. So-called premiums instead have discounts of up to $15,000.
- 07/01/2020
|
Every Upcoming Electric Car | Digital Trends
- From city cars to supercars, there are more than 50 EVs scheduled to reach showrooms during the early 2020s. Here's a comprehensive list of what's in store.
- 07/01/2020
|
Soriano Motori is reborn as a high performance electric motorcycle brand
- Not since the 1950s has a Soriano motorcycle rolled off the line. But that’s set to change as the storied Spanish motorcycle brand is rebooted by an Italian company as an all-electric motorcycle manufacturer. Soriano Motori’s new electric motorcycles And as part of the re-launch, Soriano Motori is sharing the specs on its three new […]
- 07/01/2020
|
Eagle Lightweight GT, la evolución de uno de los coches de carreras más raros y bellos del mundo
- El Lightweight E-Type de Jaguar muestra un superdeportivo clásico con las embriagadoras emociones de un Lightweight de fábrica de 1963, cuidadosa y exhaustivamente rediseñado
- 07/01/2020
|
Don't Expect a Marketing Blitz From Auto Brands on This Fourth of July
- Car buyers expecting a host of Fourth of July sales blowouts this weekend may be disappointed.
- 07/01/2020
|
The Irish Times guide to new electric cars for 2020 and 2021
- From the Audi e-Tron to Volvo XC40 P8, via Nissan and Tesla, we rate a full 36 models
- 07/01/2020
|
Plug-In Vehicles = 7.8% Market Share In Europe
- After a Covid-derived drop in April (-16% year over year), the European passenger plug-in vehicle market went back to black in May, having scored 46,800 registrations (+23%), a great performance considering the overall market is still recovering (-57% in May).
- 07/01/2020
|
Quadrilha presa em SP enganou 10 mil pessoas em todo o país e prejuízo estimado pode chegar a R$ 10 milhões, diz polícia
- Clientes pagavam por produto a preço abaixo do mercado em site de importadora, só que nunca recebiam. Operação foi feita em Jaú, no interior de São Paulo; Mauá, no ABC Paulista; e na cidade de São Paulo.
- 06/30/2020
|
Com 71 mortes, letalidade da PM de S
- Com mais de dois casos registrados por dia, o n
- 06/30/2020
|
Who Made My Car? a Comprehensive Guide to Today's Car Conglomerates | Digital Trends
- Who owns the world's biggest car brands? The answer isn't always straight-forward; the industry is a latticework of mergers, acquisitions, and partnerships.
- 06/30/2020
|
Killer drug driver mowed down father-of-four on crossing at 60mph
- Rizwan Ali, 26, of Bolton, jailed for three years and five months after he admitted to ploughing into 65-year-old Colin Olawumi at 55mph in his Range Rover as the victim was walking home on crossing.
- 06/30/2020
|
Découvrez le Fortress Mk2, le nouveau blindé agile d'Arquus
- Le Fortress Mk2 est le dernier bijou technologique sorti des usines de l’entreprise française Arquus. Grâce à son blindage plus résistant mais aussi plus léger, ce véhicule peut transporter 11 soldats
- 06/30/2020
|
30 Cars Worth Splurging On
- See some of the best luxury sedans and more entry-level buys.
- 06/30/2020
|
Estos son los coches con más y menos averías en los primeros 90 días de uso
- A veces, elegir el coche que mejor se adapta a nuestras necesidades no es sencillo, aunque también es cierto que lo último que buscamos en un vehículo nuevo es que sufra averías
- 06/30/2020
|
Ford F-150 The Perfect Anti-Cybertruck, Tons Of Autonomy News, & More — CleanTech Weekly News Show #14
- This is the 14th broadcast of CleanTechnica’s weekly news show. This week’s show covers a lot of autonomy news, climate news you haven't heard before, the new Ford F-150, Tesla Cybertruck revelations, and more.
- 06/30/2020
|
Top gear: With Mercedes Benz, Porsche, and KIA as its top clients, Shutterdrives transforms the way cars are reviewed
- Bootstrapped Shutterdrives, founded by Zahoor Hassan, is a digital platform for automotive reviews and news, experience drives, and travelogues.
- 06/30/2020
|
2020 Lexus LS 500 AWD Test Drive And Review: Looking Up The Ladder
- Are full-size premium sedans still the aspirational standard?
- 06/30/2020
|
El final de ‘Las chicas del cable’, el final de un ciclo para sus creadoras
- La primera serie española de Netflix, que termina este viernes, situó a su productora como referente en el mercado internacional
- 06/29/2020
|
Mercedes-Benz reportedly pulls the plug on its subscription service after poor sales
- The latest alternate ownership model to be phased out.
- 06/29/2020
|
Volvo, accordo con Waymo per guida autonoma servizio taxi - Componenti & Tech
- Obiettivo è arrivare all'utilizzo del driveless di livello 4 (ANSA)
- 06/29/2020
|
Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter an Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020
- SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2020 / Jaguar Health, Inc. (JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc., (collectively, the "Company") have jointly entered into an amendment to the accounts receivable purchase agreement with Oasis Capital, LLC ("Oasis"), dated May 12, 2020, pursuant to which Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company's Mytesi® drug product to Cardinal Health for the period of May 2020 through June 24, 2020 (the "Spring 2020 Accounts Receivable"). The Spring 2020 Accounts Receivable have a gross value of $2,859,132.
- 06/29/2020
|
Celebrity Endorsement Deals With Insane Payouts
- Learn which celebrity endorsements were the biggest moneymakers.
- 06/29/2020
|
Audi sets hopes high on updated Q5 SUV
- Significant upgrades for 2021 model include new infotainment system with 10-inch touchscreen, not rotary controller
- 06/29/2020
|
"Quand j'ai acheté la Porsche, la puissance de ma Jaguar m'a manqué"
- Cela fait 10 ans que Christophe D'haesleer, gérant de la boutique Marie-Claire Zoute à Knokke, participe au Zoute Rally avec sa Jaguar d'après-guerre et sa Porsche 356. Il y a cinq ans, il a commencé à organiser un rallye lui-même: le Rally Marie-Claire Zoute.
- 06/29/2020
|
Probamos el BMW 840i, el gran turismo de BMW
- El BMW 840i es el heredero de una saga de GT que BMW inició en 1990 y que desapareció en 1999. Veinte años después vuelve a la escena y éste es el formidable resultado.
- 06/29/2020
|
Centaurus Metals share price soars 33% on maiden JORC mineral resource
- The Centaurus Metals Limited (ASX: CTM) share price is surging after the company announced a maiden JORC resource for its Jaguar Project.
- 06/29/2020
|
Pro Photos Of Tesla Cybertruck, Offshore Wind Innovation, EV Revolution — CleanTechnica Top 20
- From some beautiful, exclusive photos of the Tesla Cybertruck to offshore wind innovations to the EV revolution that is now well underway, last week's top stories on CleanTechnica were varied and fun.
- 06/29/2020
|
ComfortDelGro to roll out 'fastest' DC fast charger for EVs in Singapore from July 1
- COMFORTDELGRO on Monday said it will roll out what it claims to be Singapore's fastest public commercial direct current (DC) charger for its cabbies and electric vehicle (EV) owners from July 1. Read more at The Business Times.
- 06/29/2020
|
Centaurus Metals reveals shallow high-grade nickel resource for Jaguar
- Centaurus Metals (ASX: CTM) has revealed a maiden nickel resource for its Brazil-based Jaguar project, with the majority of the resource within 200m of surface.
- 06/29/2020
|
Waymo And Volvo Form Exclusive Self-Driving Partnership
- Waymo and Volvo announced an “exclusive” partnership to integrate Waymo’s self-driving technology onto Volvo’s vehicular platform.
- 06/29/2020
|
Men charged in fatal Stamford jewelry store robbery to be arraigned
- The sister of Marco Jewelers owner Mark Vuono expressed thanks to law enforcement for their work on the case. Vuono's son has reopened the jewelry store.
- 06/28/2020
|
Mike Tindall's dad says Zara is 'pleased she wasn't given HRH title'
- Speaking to The Sunday Times, Yorkshireman Philip Tindall, 73, told how Zara has always been 'so pleased' about the decision - adding that Zara and Mike have a small circle of friends 'they trust'.
- 06/28/2020
|
Audi e-tron: driving the first all-electric Audi
- The e-tron is Audi's first fully electric car
- 06/28/2020
|
Indian Air Force now ready to take on China within 8 minutes if situation demands
- Indian Air Force is on high alert and is closely monitoring situation unfolding not only at Line of Actual Control (LAC) in Ladakh but the entire stretch of Sino-Indian border. Ever since the standoff between India and China began, Indian Air Force has been amping up its capabilities.
- 06/28/2020
|
Maddie suspect's Brit neighbour fears she destroyed DNA evidence while cleaning
- A BRIT neighbour of Madeleine McCann’s paedo suspect fears she washed away vital evidence after cleaning his squalid home. Ruth Maclean lived next to Christian B in Sitio de Lakes, near Praia…
- 06/28/2020
|
First Drive: The Volkswagen e-Up! brings fun to the EV segment - Evening Express
- What is it?
In the race to gain EV supremacy, it seems that many manufacturers have forgotten that often the best application of electric technology is in smaller city cars. After all, the current crop of EVs are quite large; Jaguar’s I-Pace is huge, for instance, while Audi’s e-Tron is a dominating force out on the road. Then there is the myriad of crossovers like the Hyundai Kona Electric and the Kia Soul Electric.
- 06/28/2020
|
IAF watching Chinese bases, sure of matching air power
- There has been “no major or fresh infusion of assets” by the Peoples Liberation Army-Air Force at Hotan and Kashgar in Xinjiang as well as Gargunsa, Lhasa-Gonggar and Shigatse airbases said defence sources. But the Indian Army and IAF moved forward surface-to-air missiles and other such systems to tackle aerial threats.
- 06/28/2020
|
A special Range Rover, job cuts and more - your latest JLR round-up
- As always there is lots going on involving Britain's biggest car maker
- 06/28/2020
|
Jaguar Future At Risk As Owner Tata Motors Ponders JLR Recovery Plan
- Jaguar’s future is on the line as its Indian owners, Tata Motors, decides the future of this coronavirus-devastated company. Will its range of sedans be cut back, or will it be sold to another company?
- 06/28/2020
|
Si le llaman al móvil no lo coja, es Stephen King
- Publicamos el comienzo de «El teléfono del señor Harrigan», una de las cuatro novelas cortas e inéditas que el escritor reúne en «La sangre manda» (Plaza & Janés), que sale el día 2 de julio
- 06/27/2020
|
Maddie suspect's neighbour destroyed any likely DNA from his house
- Ruth Maclean lived next door to 'monster' Christian Brueckner, 43, in the hamlet of Sitio de Lakes, near Praia de Luz, for years.
- 06/27/2020
|
China will have to pay a heavy price for military misadventure in eastern Ladakh: Experts
- The experts have also referred to China's tariff war with the US, growing bickering with Australia on trade-related issues and the fast deteriorating situation in Hong Kong.
- 06/27/2020
|
2020 Chevrolet Bolt boasts greater range and great value (review)
- The Bolt is no sports car, but proves responsive, tossable and fun-to-drive.
- 06/27/2020
|
Economic cost of misadventure in Ladakh will be massive for China: Experts
- The experts have also referred to China's tariff war with the US, growing bickering with Australia on trade-related issues and the fast deteriorating situation in Hong Kong
- 06/27/2020
|
Galwan clash ‘huge mistake’ by China, world already fighting Covid-19: Experts
- China will have to pay a heavy price for military misadventure in eastern Ladakh: experts
- 06/27/2020
|
Wheels & Deals: BMW unveils M5; plus other industry news from VW and Land Rover
- Declan Colley rolls out the latest news from BMW, Volkswagen, Land Rover and other big manufacturers
- 06/27/2020
|
PM promises workers hit by austerity WON'T pay to revamp economy
- In a major announcement on Tuesday, the Prime Minister will set out plans for a 'decade of investment' by bringing forward infrastructure spending and deregulating the planning system.
- 06/27/2020
|
Electric cars are ‘opportunity’ and give freedom to car firms says top designer Ian Callum
- FORMER Jaguar and Aston Martin designer Ian Callum has described electric cars as a "huge opportunity" to give "freedom" to manufacturers.
- 06/27/2020
|
2021 Cars and Trucks That Are Worth Saving Up for Next Year
- If you're looking, these cars are something special.
- 06/26/2020
|
A-to-Z guide to new cars: Avail of an offer now or wait for what’s in store later in the year?
- There are plenty of shiny new car models on the way to look forward to. Here’s a rundown of the ones we know about, plus a few offers to avail of ...
- 06/26/2020
|
Interest in campervans surges as lockdown eases
- Manufacturers say they are getting calls from both stir-crazy couples and families wanting to explore the country safely and avoid the hassle of travelling overseas and quarantine on return.
- 06/26/2020
|
Career criminals sold on stolen cars worth thousands of pounds
- Ryan Parry, 31, and Matthew Price, 36, were jailed after running an operation in Caerphilly which saw them receive stolen cars and sold them on
- 06/26/2020
|
Un concierge pour voitures de collection
- Passionné de vitesse et de belle mécanique, Claude-Philippe Laroche a fini par en faire son métier: l’entreposage de véhicules d’exception avec un service additionnel.
- 06/26/2020
|
Boris Johnson narrowly avoids shaking hand with woman saying he's 'just washed'
- Boris Johnson was offered handshake with a local resident at the Docklands but was quickly rejected. The prime minister then stressed his hands were clean while maintaining social distancing rules
- 06/26/2020
|
Glastonbury 2020: BBC announces exciting update and other highlights - Evening Express
- The BBC has been granted permission for a skeleton production and presentation crew to broadcast live from Worthy Farm this weekend on what would have been Glastonbury’s 50th anniversary celebration.
- 06/26/2020
|
Glastonbury 2020: BBC announces exciting update and other highlights
- The festival would have celebrated its 50th anniversary this weekend.
- 06/26/2020
|
Probamos el BMW 840i, el gran turismo de BMW
- El BMW 840i es el heredero de una saga de GT que BMW inició en 1990 y que desapareció en 1999. Veinte años después vuelve a la escena y éste es el formidable resultado.
- 06/26/2020
|
Probamos el BMW 840i, el gran turismo de BMW
- El BMW 840i es el heredero de una saga de GT que BMW inició en 1990 y que desapareció en 1999. Veinte años después vuelve a la escena y éste es el formidable resultado.
- 06/26/2020
|
Probamos el BMW 840i, el gran turismo de BMW
- El BMW 840i es el heredero de una saga de GT que BMW inició en 1990 y que desapareció en 1999. Veinte años después vuelve a la escena y éste es el formidable resultado.
- 06/26/2020
|
Army Chief Naravane Briefs Defence Minister Rajnath Singh on Eastern Ladakh Situation
- The Army Chief was in Ladakh on a two-day visit from June 23 to take stock of the situation.
- 06/26/2020
|
Army Chief briefs Rajnath on eastern Ladakh situation
- Army Chief Gen MM Naravane on Friday briefed Defence Minister Rajnath Singh on the overall situation in eastern Ladakh as well as India's military preparedness in the region where Indian and Chinese troops are locked in a bitter standoff, official sources said.
- 06/26/2020
|
Tesla, dernière marque en termes de qualité !
- Chaque année, la société JD Power livre son rapport annuel de qualité initiale des véhicules. Si la marque en tête a de quoi étonner, c’est surtout l’entrée remarquée de Tesla dans ce classement qui choque ! Parmi les nombreuses études de JD Power, ...
- 06/26/2020
|
2020 Land Rover Range Rover Velar Review: V8 Muscle | Digital Trends
- The 2020 Land Rover Range Rover Velar gains a special SVAutobiography Dynamic Edition model with a 550-horsepower V8. Does that move the needle for this SUV?
- 06/26/2020
|
Élite: Los fichajes de la temporada 4, según las filtraciones
- Élite regresará a Netflix con una cuarta temporada en la que habrá varias incorporaciones. Algunas de ellas parecen haberse filtrado, ya que los protagonistas de la serie se han re
- 06/26/2020
|
Horóscopo semanal alternativo: predicciones diarias del 22 al 28 de junio
- Desde tiempos inmemoriales la humanidad ha consultado las predicciones basadas en la astrología, la numerología, animales de poder, tarot…
- 06/26/2020
|
Chorley garage put on the market after 28 years as owner plans retirement
- “I think if you talk to villagers, they’d probably say they want it to stay as a garage as well."
- 06/26/2020
|
Mouni Roy shares old photos with Sushant Singh Rajput and Ankita Lokhande; asks 'Remember?' - Times of India
- The news of Pavitra Rishta actor and Bollywood star Sushant Singh Rajput's demise is slowly sinking in but its void will never be filled. Actor Mouni
- 06/26/2020
|
Waymo and Volvo to Build an All-new Electric Robo-taxi | Digital Trends
- Waymo has announced yet another partnership, this time with Volvo. The pair will join forces to build an all-new autonomous car for ridesharing services.
- 06/26/2020
|
Quality And Tesla: Are They Compatible?
- When Tesla Motors landed, unofficially, at the bottom of the most recent J.D. Power Initial Quality rankings it prompted the question does Tesla offer high-quality vehicles?
- 06/26/2020
|
U.K. Car Output Drops 95% in May, Spurring Cry for Help - BNN Bloomberg
- Britain’s car production plunged to the lowest level for May since 1946 after carmakers had to idle factories to help prevent the spread of the coronavirus pandemic.
- 06/25/2020
|
Tesla rated as lowest-quality car brand in 2020 study
- The 34th annual J.D. Power survey, which gauges vehicles' performance in their first 90 days, has included Elon Musk's electric car company for the first time.
- 06/25/2020
|
Jaguar Restaurant Highlights their Signature Ceviches
- Check out the latest community post from one of your neighbors. (The views expressed in this post are the author’s own.)
- 06/25/2020
|
Jaguar I-PACE Gets More Bling — A Lot More Bling!
- Jaguar has announced that the I-PACE is getting significantly upgraded infotainment, charging, driver-assist technology, and design. Let's have a look.
- 06/25/2020
|
Sex addict claims hot female gamers caused him to injure his penis
- Excessive gaming is known to damage one’s joystick. A California sex addict is suing the video streaming platform Twitch for $25 million after claiming that the site’s overabundance of …
- 06/25/2020
|
Cadillac will unveil its electric SUV Lyriq on August 6th
- Here come’s Cadillac’s first EV
- 06/25/2020
|
Waymo partners with Volvo on ride-hailing vehicles - 9to5Google
- Besides operating a ride-hailing service, Waymo is offering its self-driving technology to carmakers. The latest deal sees Waymo partner with the Volvo...
- 06/25/2020
|
High-Powered Wireless EV Charging — Is It Finally Time?
- As long as I've been covering electric vehicles (nearly a decade) there's been a debate in the industry about the potential for high-powered wireless charging.
- 06/25/2020
|
Jaguar relance la production d’un moteur vieux de plus de 60 ans !
- Abandonné en 1968, le moteur 3,8 litres XK est de nouveau produit par Jaguar. Une nouvelle qui va ravir les propriétaires d’anciens modèles de la marque anglaise.
- 06/25/2020
|
